EU Clinical Trials Tracker 2026 - Latest CTIS Authorisations Across Europe

Colonization by methicillin-resistant S. aureus and gut microbiota in users of pre-exposure prophylaxis (PrEP) and people living with HIV (PLHIV) with STIs.
Instituto De Investigacion Marques De Valdecilla · 392 participants

📍 Spain

2025-525150-19-01 on CTIS ↗

Phase I/II Neoplasms Authorised 06/08/2026

Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer

Advanced solid tumours
Orion Corporation · 104 participants

📍 Spain

2026-525864-17-00 on CTIS ↗

Phase II Immune System Diseases Authorised 05/08/2026

VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study

People with stage 1 or stage 2 T1D between the ages of 7 and 45
Assistance Publique Hopitaux De Paris · 50 participants

📍 France

2025-524318-27-00 on CTIS ↗

Phase III Immune System Diseases Authorised 05/08/2026

A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART

HIV Infections
Viiv Healthcare UK Limited · 81 participants

📍 Spain

2024-518511-19-00 on CTIS ↗

Phase I Hormonal diseases Authorised 05/08/2026

An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over pilot comparative bioavailability study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1,000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.

treatment of diabetes
Vianex S.A. · 18 participants

📍 Czechia

2026-526397-17-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 05/08/2026

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP

Chronic Kidney Disease, Heart Failure, Coronary Artery disease
Novartis Pharma AG · 43 participants

📍 Germany

2026-525974-21-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 04/08/2026

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

Hypereosinophilic Syndrome (HES), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Asthma
AstraZeneca AB · 15 participants

📍 Belgium · Italy · Netherlands

2025-523307-29-00 on CTIS ↗

Phase IV Nutritional and Metabolic Diseases Authorised 04/08/2026

A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults with Obesity

Obesity
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) · 150 participants

📍 Germany

2026-526200-69-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 04/08/2026

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

Idiopathic Pulmonary Fibrosis
AstraZeneca AB · 109 participants

📍 Germany · Spain · Greece · Bulgaria · Italy · France · Denmark

2025-525016-41-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 04/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

type 2 diabetes mellitus
AstraZeneca AB · 200 participants

📍 Poland · Germany · Bulgaria · Czechia

2025-523935-20-00 on CTIS ↗

Phase I Not possible to specify Authorised 04/08/2026

Study in healthy volunteers to evaluate how the body processes Iadademstat and if food affects it

Healthy Volunteers
Oryzon Genomics S.A. · 30 participants

📍 Spain

2026-525953-35-00 on CTIS ↗

Phase I Neoplasms Authorised 04/08/2026

A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer

Advanced Cancer
Sumitomo Pharma America Inc. · 43 participants

📍 Spain · Bulgaria · Poland · Romania

2025-524652-63-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

type 2 diabetes mellitus
AstraZeneca AB · 183 participants

📍 Germany · Bulgaria · Spain · Denmark

2025-523940-12-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)

type 2 diabetes mellitus
AstraZeneca AB · 360 participants

📍 Slovakia · Poland · Czechia · Germany · Hungary · Greece · Denmark

2025-523941-81-00 on CTIS ↗

Phase IV Musculoskeletal Diseases Authorised 03/08/2026

Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT

Full-thickness cartilage defects of the knee
Medical Center - University Of Freiburg · 166 participants

📍 Germany

2026-526179-49-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 03/08/2026

RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»

Adult patients with a diagnosis of fibrotic Hypersensitivity Pneumonitis (HP) (“definite” or “high confidence”) after multi-disciplinary discussion (MDD) with a mild to moderate disease severity, and never treated for fibrotic HP.
Assistance Publique Hopitaux De Paris · 120 participants

📍 France

2025-521591-64-00 on CTIS ↗

Phase III Neoplasms Authorised 03/08/2026

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG · 25 participants

📍 France · Austria · Spain

2025-523724-47-00 on CTIS ↗

Phase I Neoplasms Authorised 03/08/2026

A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corp. · 40 participants

📍 Italy · Belgium · Germany

2026-525360-18-00 on CTIS ↗

Phase III Skin and Connective Tissue Diseases Authorised 03/08/2026

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Systemic sclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 124 participants

📍 Denmark · Sweden · Netherlands · Germany · Belgium · France · Greece · Norway · Finland · Czechia · Portugal · Bulgaria · Spain · Estonia · Lithuania

2025-523884-39-00 on CTIS ↗

Phase I Neoplasms Authorised 03/08/2026

Feasibility clinical trial of the sequential combination of AloCelyvir and activated tumor-infiltrating lymphocytes (TILs) for the treatment of children and young adults with advanced neuroblastoma

High-risk relapsed/refractory (R/R) neuroblastoma (NB).
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa · 15 participants

📍 Spain

2025-522006-21-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 03/08/2026

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

Epilepsy
Ovid Therapeutics Inc. · 12 participants

📍 Netherlands

2026-527114-23-00 on CTIS ↗

Phase I Immune System Diseases Authorised 03/08/2026

Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)

Therapy-resistant and progressing lung fibrosis in the course of an autoantibody-positive autoimmune disease like Systemic Sclerosis, ANCA-associated Vasculitis, seropositive Rheumatoid Arthritis, Sjögren’s disease, anti-Synthetase Syndrome or other autoimmune diseases
Universitaetsklinikum Heidelberg AöR · 10 participants

📍 Germany

2024-519592-26-00 on CTIS ↗

Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

Moderately to Severely Active Crohn’s Disease
Janssen Cilag International · 194 participants

📍 Norway · Romania · Austria · Italy · Slovakia · Germany · Hungary · Netherlands · Belgium · France · Portugal · Czechia · Poland · Spain · Greece

2026-525922-39-00 on CTIS ↗

Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International · 302 participants

📍 France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal

2026-525923-26-00 on CTIS ↗

Phase I Immune System Diseases Authorised 02/08/2026

A Phase I Study to Evaluate ELA822

Healthy Volunteers
Electra Therapeutics Inc. · 45 participants

📍 Austria

2025-524911-34-00 on CTIS ↗

Phase II Therapeutics Authorised 01/08/2026

Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study

Chronic postsurgical pain (CPSP)
Aalborg University Hospital · 15 participants

📍 Denmark

2026-525669-33-00 on CTIS ↗

Phase II Mental Disorders Authorised 01/08/2026

The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.

Anorexia nervosa
Slagelse Hospital · 62 participants

📍 Denmark

2025-524939-39-02 on CTIS ↗

Phase I Nervous System Diseases Authorised 31/07/2026

A Randomised, Placebo‑Controlled Trial to Assess Effect of IMU‑838 on QT/QTc

Multiple sclerosis
Immunic AG · 20 participants

📍 Belgium

2026-526859-54-00 on CTIS ↗

Phase I Neoplasms Authorised 31/07/2026

A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours)

solid tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 39 participants

📍 Spain

2026-525785-22-00 on CTIS ↗

Phase III Anesthesia and Analgesia Authorised 31/07/2026

Perioperative Intravenous Metamizole in Laparoscopic Cholecystectomy: A rondomized, double blind, clinical trial.

Post operative pain relief in Patients undergoing laparoscopic cystectomy in day-surgery clinic
UZ Leuven · 76 participants

📍 Belgium

2026-526531-18-00 on CTIS ↗

Phase II Pathological Conditions, Signs and Symptoms Authorised 31/07/2026

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

End stage renal failure
Medical University Of Vienna · 6 participants

📍 Austria

2025-523222-40-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 31/07/2026

A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

Drug resistant focal epilepsy related to focal cortical dysplasia
PannTheraPi · 15 participants

📍 France

2026-525161-40-00 on CTIS ↗

Phase I Pathological Conditions, Signs and Symptoms Authorised 30/07/2026

Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer

HER2 mutation positive NSCLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting · 20 participants

📍 Netherlands

2026-525568-17-00 on CTIS ↗

Phase I/II Nervous System Diseases Authorised 30/07/2026

A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3

Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS · 50 participants

📍 France · Denmark · Spain · Portugal

2025-525111-17-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 30/07/2026

Nav 1.8 and 1.7 combo trial

Pain
Niroda Therapeutics Inc. · 96 participants

📍 Netherlands

2026-526867-39-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 30/07/2026

Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions

Not applicable (submitted trial is a bioavailability trial in healthy participants).
Laboratorios Cinfa S.A. · 36 participants

📍 Czechia

2026-525836-41-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 30/07/2026

J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
Eli Lilly & Co. · 145 participants

📍 Hungary · Czechia · Spain · Netherlands

2025-524858-34-00 on CTIS ↗

Phase I Immune System Diseases Authorised 30/07/2026

Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function

Renal Impairment
Sanofi-Aventis Recherche & Developpement · 8 participants

📍 Germany

2026-525707-27-00 on CTIS ↗

Phase III Neoplasms Authorised 29/07/2026

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)

Follicular Lymphoma
AstraZeneca AB · 15 participants

📍 Denmark

2023-510098-33-01 on CTIS ↗

Phase I Neoplasms Authorised 29/07/2026

A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy

Advanced or metastatic solid tumours
Pliant Therapeutics Inc. · 15 participants

📍 Spain

2026-526116-36-00 on CTIS ↗

Phase III Mental Disorders Authorised 29/07/2026

B-HAPPI: Bipolar disorder and high-dose adjunctive pramipexole for anhedonic depression – a phase III, double-blind, randomized controlled trial

Bipolar disorder
Region Skane · 186 participants

📍 Sweden

2026-526383-20-00 on CTIS ↗

Phase I/II Skin and Connective Tissue Diseases Authorised 29/07/2026

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age

Acne
Sanofi Pasteur Inc. · 189 participants

📍 Spain · Germany · Poland

2025-521740-38-00 on CTIS ↗

Phase IV Mental Disorders Authorised 29/07/2026

Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study

Major depressive disorder (MDD)
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. · 120 participants

📍 Bulgaria · Poland · Hungary

2025-523267-38-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 29/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF); on background SGLT2i.
AstraZeneca AB · 2343 participants

📍 Spain · Hungary · Germany · Poland · Italy · Bulgaria · Netherlands · Austria · Romania · Sweden · France · Greece · Slovakia · Czechia

2026-526304-79-00 on CTIS ↗

Phase I Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/07/2026

An Open-label Phase 1 Study in Healthy Adult Participants to Investigate the Effect of Itraconazole on the Blood Levels of Engasertib

This clinical trial is performed in healthy participants; the planned indication: Treatment of Hereditary hemorrhagic telangiectasia (HHT)
Vaderis Therapeutics AG · 27 participants

📍 Germany

2026-526311-11-00 on CTIS ↗

Phase II Neoplasms Authorised 28/07/2026

A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC)
Puma Biotechnology Inc. · 30 participants

📍 France · Poland · Spain

2026-525382-47-00 on CTIS ↗

Phase I/II Neoplasms Authorised 28/07/2026

Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma

Unresectable Stage III or Stage IV Cutaneous Melanoma
Karolinska University Hospital · 105 participants

📍 Sweden

2026-526821-16-00 on CTIS ↗

Phase IV Nervous System Diseases Authorised 28/07/2026

Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.

Multiple Sclerosis and Neuromyelitis optica spectrum
Centre Hospitalier Universitaire De Toulouse · 160 participants

📍 France

2025-525106-37-00 on CTIS ↗

Phase II Immune System Diseases Authorised 28/07/2026

OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial

Patients with newly or active diffuse Systemic sclerosis at the time of screening.
Assistance Publique Hopitaux De Paris · 74 participants

📍 France

2025-524003-68-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 28/07/2026

STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)

ischemic heart disease
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz · 3500 participants

📍 Spain · Norway

2026-525933-22-00 on CTIS ↗

Phase I Neoplasms Authorised 27/07/2026

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer

Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG · 44 participants

📍 Portugal · Denmark · Spain · France

2025-522209-40-00 on CTIS ↗

Phase I Neoplasms Authorised 27/07/2026

A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms

Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Intermediate-1, Intermediate-2, or High-Risk Primary Myelofibrosis, High-risk Polycythemia Vera
Prelude Therapeutics Inc. · 22 participants

📍 Italy · France · Spain

2026-525484-40-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 27/07/2026

A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial

Chronic Coronary Syndrome in patients undergoing percutaneous coronary intervention (PCI)
Azienda Ospedaliera Universitaria Gaetano Martino Messina · 500 participants

📍 Italy

2026-526368-18-00 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 27/07/2026

A first-in-human, randomized, double-blind, placebo-controlled, 3-part study assessing the safety, tolerability, pharmacodynamics and pharmacokinetics of GL0071 after single and repeated ascending subcutaneous doses in healthy normal weight, overweight and obese participants, as well as a 12-week treatment randomized, double blind, placebo-controlled exploratory Proof-of-Concept study in overweight and obese participants.

Type 2 diabetes mellitus, Overweight
Sun Pharmaceutical Industries Limited · 124 participants

📍 Belgium

2025-524233-45-00 on CTIS ↗

Phase II Neoplasms Authorised 27/07/2026

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA
Cancer Research UK · 26 participants

📍 Spain · France · Germany · Norway

2025-522757-19-00 on CTIS ↗

Phase II Neoplasms Authorised 27/07/2026

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Janssen Cilag International · 6 participants

📍 Spain

2025-524816-13-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S · 1140 participants

📍 Greece · Portugal · France · Slovakia · Bulgaria · Netherlands · Romania · Italy · Austria · Poland · Hungary · Spain · Czechia · Belgium

2025-522488-14-00 on CTIS ↗

Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 27/07/2026

4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

Barth Syndrome
Stealth Biotherapeutics Inc. · 22 participants

📍 Ireland · Netherlands · France · Italy

2025-523837-25-00 on CTIS ↗

Phase I/II Neoplasms Authorised 27/07/2026

Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute myeloid leukemia and Blastic plasmacytoid dendritic cell neoplasm
Fondazione Tettamanti, Fondazione IRCCS San Gerardo Dei Tintori · 18 participants

📍 Italy

2025-524977-18-00 on CTIS ↗

Phase I Parasitic Diseases Authorised 27/07/2026

A clinical trial of MK-3868 in healthy participants (MK-3868-001)

Malaria
Merck Sharp & Dohme LLC · 16 participants

📍 Belgium

2026-526674-17-00 on CTIS ↗

Phase III Neoplasms Authorised 27/07/2026

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG · 125 participants

📍 Italy · Greece · Spain · Belgium · France · Austria · Germany

2025-523819-11-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 27/07/2026

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.

Atrial Fibrillation
Milestone Pharmaceuticals Inc. · 200 participants

📍 Netherlands

2024-516251-40-01 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 27/07/2026

Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Medical University Of Vienna · 10 participants

📍 Austria

2026-526526-41-01 on CTIS ↗

Phase IV Therapeutics Authorised 27/07/2026

Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer

Venous thromboembolism (in bladder cancer patients)
HUS-Yhtymae · 210 participants

📍 Finland

2024-518861-90-00 on CTIS ↗

Phase I Not possible to specify Authorised 27/07/2026

A study in healthy people to measure how different doses of verducatib affect the heart

Healthy volunteer trial
Boehringer Ingelheim International GmbH · 56 participants

📍 Germany

2026-525813-30-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)

Participants Living with Obesity or Overweight with at least 1 comorbidity with or without Type 2 Diabetes Mellitus
AstraZeneca AB · 1010 participants

📍 Spain · Germany · Italy · Poland

2025-524688-19-00 on CTIS ↗

Phase III Neoplasms Authorised 27/07/2026

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

Advanced or Metastatic HR+/HER2- Breast Cancer
BeOne Medicines I GmbH · 233 participants

📍 Poland · Italy · Germany · France · Spain

2025-523960-19-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 24/07/2026

Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK

parkinson disease
Centre Hospitalier Universitaire De Toulouse · 39 participants

📍 France

2026-525862-23-00 on CTIS ↗

Phase II Neoplasms Authorised 24/07/2026

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

triple‑negative breast cancer
Institut Paoli Calmettes · 84 participants

📍 France

2025-525040-18-00 on CTIS ↗

Phase II Not possible to specify Authorised 24/07/2026

functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study

Arthritis rheumatoid and finger osteoarthritis
Centre Jean Perrin · 80 participants

📍 France

2025-523650-14-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 24/07/2026

VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)

Parapneumonic pleural infection/pleural empyema
Amsterdam UMC Stichting · 164 participants

📍 Netherlands

2026-526289-25-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 24/07/2026

Immune Cell Therapy for People with Early, Active Multiple Sclerosis

Newly diagnosed highly-active Multiple Sclerosis
Medizinische Hochschule Hannover · 10 participants

📍 Germany

2025-522409-39-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 24/07/2026

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

Spinal Muscular Atrophy
Biogen Idec Research Limited · 40 participants

📍 Finland · Spain · Italy · Poland · Ireland · Germany · France

2025-524054-34-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 24/07/2026

A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

non-valvular atrial fibrillation
Ribocure Pharmaceuticals AB · 150 participants

📍 Norway · Denmark · Poland · Sweden

2026-525417-31-00 on CTIS ↗

Phase I Diagnosis Authorised 24/07/2026

161Tb-labeled Gastrin Analogue - A Novel Tool for Precision Treatment of Advanced Medullary Thyroid Cancer

Thyroid cancer
Uniwersytet Jagiellonski Collegium Medicum · 30 participants

📍 Poland

2025-524951-30-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 24/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

Chronic kidney disease (CKD) in adults, with specified ranges of eGFR and albuminuria (UACR), irrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.
AstraZeneca AB · 1600 participants

📍 Czechia · Italy · Hungary · Romania · Bulgaria · Sweden · Denmark · Poland · Spain · Norway · Finland · Greece · France · Germany

2025-523994-41-00 on CTIS ↗

Phase III Hemic and Lymphatic Diseases Authorised 23/07/2026

Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)

Multiple myeloma
Polish Myeloma Consortium · 248 participants

📍 Poland

2025-525097-11-00 on CTIS ↗

Phase I Respiratory Tract Diseases Authorised 23/07/2026

A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
Genentech Inc. · 104 participants

📍 Germany

2025-525042-22-00 on CTIS ↗

Phase II Neoplasms Authorised 23/07/2026

Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors

Metastatic solid tumors, with the following specific indications: Non–Small Cell Lung Cancer (NSCLC), metastatic, PD-(L)1–refractory/resistant Gastric adenocarcinoma, metastatic, PD-(L)1–refractory/resistant Colorectal cancer (microsatellite stable, MSS), metastatic, immunotherapy‑naïve Pancreatic adenocarcinoma, metastatic, immunotherapy‑naïve
Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets · 30 participants

📍 Italy

2025-524125-40-01 on CTIS ↗

Phase II Immune System Diseases Authorised 23/07/2026

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)

VEXAS Syndrome
Sironax USA Inc. · 24 participants

📍 Italy

2025-524918-28-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 23/07/2026

IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH · 91 participants

📍 Germany · Spain

2026-525185-21-00 on CTIS ↗

Phase III Hormonal diseases Authorised 23/07/2026

A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

Classic Congenital Adrenal Hyperplasia (CAH)
Neurocrine Biosciences Inc. · 71 participants

📍 Czechia · Germany · Sweden · Portugal · Romania · Bulgaria · Italy · Austria · Spain

2025-524282-24-00 on CTIS ↗

Phase III Not possible to specify Authorised 23/07/2026

Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.

No medical condition
Chemo Research S.L. · 1550 participants

📍 Sweden · Czechia · Spain · Hungary · Poland · Finland · Romania

2026-525727-24-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 23/07/2026

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

Huntington’s Disease
Skyhawk Therapeutics Inc. · 110 participants

📍 Germany · Spain

2025-522263-14-00 on CTIS ↗

Phase I/II Respiratory Tract Diseases Authorised 22/07/2026

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

Advanced ALK-positive NSCLC
Triana Biomedicines Inc. · 4 participants

📍 France · Italy · Germany · Spain

2025-524418-27-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 22/07/2026

An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy

Parkinson's disease
Tridem Bioscience FlexCo · 8 participants

📍 Austria

2026-526294-42-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 22/07/2026

Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)

Respiratory syncytial virus infection–related respiratory disease
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana · 100000 participants

📍 Spain

2026-526804-59-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 22/07/2026

Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)

Major cardiovascular events (MACE), spontaneous intracerebral hemorrhage
Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International · 312 participants

📍 Spain · Belgium

2025-523435-18-00 on CTIS ↗

Phase IV Immune System Diseases Authorised 22/07/2026

Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?

Diabetes
Radboud universitair medisch centrum Stichting · 100 participants

📍 Netherlands

2026-525909-13-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 22/07/2026

Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)

advanced gastric cancer
Vall D Hebron Institute Of Oncology · 38 participants

📍 Spain

2026-525620-23-00 on CTIS ↗

Phase I Neoplasms Authorised 22/07/2026

Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma

surgically resectable recurrent high-grade glioma
Vall D Hebron Institute Of Oncology · 10 participants

📍 Spain

2025-524359-30-00 on CTIS ↗

Phase I/II Immune System Diseases Authorised 22/07/2026

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis

Refractory, difficult-to-treat Rheumatoid Arthritis
Bristol-Myers Squibb Services Unlimited Company · 21 participants

📍 Poland · Italy · Spain · Germany

2025-520666-22-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 22/07/2026

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

type 2 diabetes mellitus
AstraZeneca AB · 335 participants

📍 Poland · Hungary · Italy · Bulgaria · Germany

2025-523933-24-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 22/07/2026

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
Alnylam Pharmaceuticals Inc. · 17 participants

📍 Italy · Netherlands · Spain · Germany · Ireland

2025-523390-42-00 on CTIS ↗

Phase I Neoplasms Authorised 21/07/2026

Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors

Advanced Malignant Tumors; High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Services Unlimited Company · 20 participants

📍 Spain · France · Italy

2025-523067-38-01 on CTIS ↗

Phase III Digestive System Diseases Authorised 21/07/2026

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis
Ipsen Bioscience Inc. · 127 participants

📍 Spain · Sweden · Germany · Romania · Finland · Portugal · Austria · Italy · Denmark · Czechia · France · Netherlands · Poland · Belgium · Norway

2026-525242-29-00 on CTIS ↗

Phase II Bacterial Infections and Mycoses Authorised 21/07/2026

Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex

Intestinal colonization with vancomycin-resistant enterococci (VRE)
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP · 42 participants

📍 Germany

2026-525632-41-00 on CTIS ↗

Phase I/II Neoplasms Authorised 21/07/2026

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

Neoplasms, Prostate
Glaxosmithkline Research & Development Limited · 18 participants

📍 Netherlands · France · Spain

2025-523874-17-00 on CTIS ↗

Phase I Neoplasms Authorised 21/07/2026

A more sustainable perioperative treatment regimen for gastroesophageal cancer —replacing 5-FU with capecitabine within the FLOT regimen

Gastric Cancer, Esophageal cancer
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) · 14 participants

📍 Netherlands

2026-526209-13-00 on CTIS ↗

Phase II Immune System Diseases Authorised 21/07/2026

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

newly diagnosed amyloid light chain amyloidosis
Glaxosmithkline Research & Development Limited · 17 participants

📍 Italy · Greece · Spain

2025-522803-60-00 on CTIS ↗

Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

HIV-1
Gilead Sciences Inc. · 183 participants

📍 Poland · Italy · France · Spain · Germany · Netherlands

2025-524336-19-00 on CTIS ↗

Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

HIV-1
Gilead Sciences Inc. · 183 participants

📍 Netherlands · Poland · Germany · France · Spain · Italy

2025-524335-39-00 on CTIS ↗

Phase III Skin and Connective Tissue Diseases Authorised 21/07/2026

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

Lichen Sclerosus
Leo Pharma A/S · 205 participants

📍 Italy · France · Spain · Poland · Germany

2025-524873-17-00 on CTIS ↗

Phase II Neoplasms Authorised 21/07/2026

J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Breast Neoplasms
Eli Lilly & Co. · 361 participants

📍 Belgium · France · Italy · Germany

2025-523258-15-00 on CTIS ↗

Phase II Bacterial Infections and Mycoses Authorised 20/07/2026

DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

Patients requiring total hip arthroplasty for coxofemoral osteoarthritis
Centre Hospitalier Universitaire De Caen Normandie · 30 participants

📍 France

2025-524744-36-00 on CTIS ↗

Phase I Neoplasms Authorised 20/07/2026

Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3

Advanced Solid Tumor Types Known to Express B7-H3
Myricx Pharma Limited · 40 participants

📍 Spain

2025-524929-41-00 on CTIS ↗

Phase II Male Urogenital Diseases Authorised 20/07/2026

Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer

biochemical relapse of prostate cancer
Universitaetsklinikum Tuebingen AöR · 84 participants

📍 Germany

2025-522144-41-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 20/07/2026

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting · 58 participants

📍 Netherlands

2025-524842-89-00 on CTIS ↗

Phase II Neoplasms Authorised 20/07/2026

A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY

Multiple Myeloma (MM)
F. Hoffmann-La Roche AG · 45 participants

📍 Germany

2026-525736-42-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 20/07/2026

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca AB · 158 participants

📍 Germany · Italy · Spain · France · Sweden

2025-523908-75-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 20/07/2026

A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity

Participants with overweight or obesity
Novo Nordisk A/S · 171 participants

📍 Sweden · Greece · Hungary · Portugal

2025-524249-29-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 20/07/2026

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

Huntington’s Disease
Novartis Pharma AG · 368 participants

📍 Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary

2025-522227-99-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 20/07/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1
Alkermes Inc. · 116 participants

📍 Sweden · Finland · Belgium · Spain · Austria · Netherlands · France · Norway · Germany · Italy · Poland

2025-524711-36-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 20/07/2026

A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

Drug resistant seizures associated to Focal Cortical Dysplasia
PannTheraPi · 15 participants

📍 France

2026-525162-21-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 20/07/2026

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

Homozygous Familial Hypercholesterolemia (HoFH)
Arrowhead Pharmaceuticals Inc. · 9 participants

📍 Netherlands · Denmark · Norway · Sweden · Poland

2025-523662-24-00 on CTIS ↗

Phase I Mental Disorders Authorised 20/07/2026

A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.

Treatment of psychotic disorders like schizophrenia Treatment of levodopa-induced dyskinesia in Parkinson's disease
Celon Pharma S.A. · 68 participants

📍 Poland

2025-524936-20-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 20/07/2026

An open label multicenter phase II study to investigate the efficacy, safety and tolerability of the Obe-cel in patients with minimal residual disease (MRD) of Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL

Ph-negative CD19 positive B-precursor ALL patients in CR1 with molecular failure defined as MRD of 10-4 or greater after induction II of front-line therapy
Goethe University Frankfurt · 20 participants

📍 Germany

2025-524169-26-00 on CTIS ↗

Phase I/II Neoplasms Authorised 20/07/2026

A phase I/IIa safety, dose finding and feasibility trial of CD30/CEA CART in patients with liver metastases from CEA positive colorectal adenocarcinoma

Colorectal Adenocarcinoma
Universitaetsklinikum Regensburg AöR · 18 participants

📍 Germany

2026-526225-18-00 on CTIS ↗

Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 17/07/2026

Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)

Hereditary Spastic Paraplegia Type 50 (SPG50)
Elpida Therapeutics SPC · 12 participants

📍 Spain

2025-524576-28-00 on CTIS ↗

Phase II Pathological Conditions, Signs and Symptoms Authorised 17/07/2026

SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms

Children with refractory symptoms
Centre Leon Berard · 50 participants

📍 France

2025-523840-11-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 17/07/2026

Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome

Acute Coronary Syndrome
Fondazione Per Il Tuo Cuore Onlus Denominabile Anche Fondazione Italiana Per La Lotta Alle Malattie Cardiovascolari Onlus Ed Anche Heart Care Foundation Hcf Onlus · 600 participants

📍 Italy

2026-525740-15-00 on CTIS ↗

Phase I Not possible to specify Authorised 17/07/2026

Bioequivalence study of Vitamin D3 Pharma Patent 20,000 IU and the Vigantol 20,000 IU oral drops solutions and assessment of bioavailability in healthy volunteers

Healthy volunteers
Pharma Patent Kft. · 36 participants

📍 Hungary

2026-526224-48-02 on CTIS ↗

Phase I Not possible to specify Authorised 17/07/2026

A single center, randomized, controlled trial in healthy volunteers using dermal open flow microperfusion to assess cutaneous BE of two doxepin hydrochloride creams

No medical condition is being investigated in this clinical trial.
Medical University Of Graz · 24 participants

📍 Austria

2026-526078-18-00 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 17/07/2026

A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes

Type 1 Diabetes
Immunocore Limited · 20 participants

📍 Austria

2025-524449-28-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 17/07/2026

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease

Pulmonary hypertension secondary to interstitial lung disease
Tectonic Operating Company Inc. · 9 participants

📍 Poland · Romania · Spain

2026-525810-80-00 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 17/07/2026

Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

Healthy participants
Laboratorios Alter S.A. · 36 participants

📍 Spain

2026-527164-32-00 on CTIS ↗

Phase II Otorhinolaryngologic Diseases Authorised 17/07/2026

Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).

Oral cavity squamous cell carcinoma
Amsterdam UMC Stichting · 24 participants

📍 Netherlands

2025-523617-29-01 on CTIS ↗

Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 17/07/2026

Paracervical block with ropivacaine for pain relief in second trimester medical abortion - a double blind placebo controlled randomized trial

abortion
Karolinska Institutet · 132 participants

📍 Sweden

2025-524599-52-03 on CTIS ↗

Phase III Male Urogenital Diseases Authorised 16/07/2026

FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria

Febrile male urinary tract infections caused by Escherichia coli
Assistance Publique Hopitaux De Paris · 312 participants

📍 France

2026-525972-25-00 on CTIS ↗

Phase II Neoplasms Authorised 16/07/2026

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

neoplastic pleural effusion
Hospices Civils De Lyon · 20 participants

📍 France

2025-523482-23-00 on CTIS ↗

Phase III Not possible to specify Authorised 16/07/2026

PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin

Breast Cancer
University Hospital Of Clermont-Ferrand · 1600 participants

📍 France

2025-525020-99-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 16/07/2026

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid

Ulcerative Colitis
Microbial Resource Management Health · 109 participants

📍 Czechia · Poland · Italy

2025-524682-24-00 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 16/07/2026

A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis

Atopic dermatitis
Pharmability AB · 52 participants

📍 Sweden

2026-526343-35-00 on CTIS ↗

Phase II Otorhinolaryngologic Diseases Authorised 16/07/2026

Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025 mcg/ml and 0.050 mcg/ml) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis

Rhinitis
Eudemus Pharmaceuticals Limited · 120 participants

📍 Greece

2026-525419-16-00 on CTIS ↗

Phase III Neoplasms Authorised 15/07/2026

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants with Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Relapsed or refractory large B-cell lymphoma (r/r LBCL)
Kite Pharma Inc. · 192 participants

📍 Belgium · Germany · Poland · Czechia · Netherlands · Spain · Italy · France

2025-524403-80-00 on CTIS ↗

Phase II Pathological Conditions, Signs and Symptoms Authorised 15/07/2026

Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)

systemic lupus erythematosus pure membranous nephropathy
Assistance Publique Hopitaux De Paris · 65 participants

📍 France

2024-519985-35-00 on CTIS ↗

Phase II Not possible to specify Authorised 15/07/2026

COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial

Colorectal cancer with peritoneal metastases
Uppsala University Hospital · 60 participants

📍 Sweden

2026-526122-41-00 on CTIS ↗

Phase I/II Neoplasms Authorised 15/07/2026

Phase I/II clinical trial on the use of central nervous system administrations of CART-NKG2D or NKIL15 cells in children, adolescent and young adults with recurrent/refractory high grade Central Nervous System tumours (CINK-CAR)

Central nervous system tumours
Hospital Universitario La Paz · 30 participants

📍 Spain

2026-525876-24-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 14/07/2026

The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

Asthma
Glaxosmithkline Research & Development Limited · 229 participants

📍 Ireland · Spain · Germany · Czechia · Bulgaria · France · Belgium · Romania · Italy

2025-524463-20-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 14/07/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

Acute Ischemic Stroke
Takeda Development Center Americas Inc. · 67 participants

📍 Greece · Belgium · France · Germany

2025-522734-31-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 14/07/2026

Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation - The randomized, controlled, open-label, parallel group TRIPLE-LIPID-OUT trial

Peripheral arterial disease, Coronary artery atherosclerotic heart disease, Hypercholesterolaemia
Medical University Of Graz · 160 participants

📍 Germany · Austria

2026-525917-29-00 on CTIS ↗

Phase III Neoplasms Authorised 14/07/2026

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic colorectal cancer
Merck Healthcare KGaA · 323 participants

📍 Belgium · Germany · France · Denmark · Poland · Spain · Netherlands · Italy · Austria

2025-524648-37-00 on CTIS ↗

Phase I/II Hemic and Lymphatic Diseases Authorised 14/07/2026

FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia

Adults (≥ 18 years of age) with relapsed or refractory acute myeloid leukemia (R/R AML)
Karolinska University Hospital · 26 participants

📍 Sweden

2026-526961-76-00 on CTIS ↗

Phase II Neoplasms Authorised 14/07/2026

A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT

cutaneous squamous cell carcinoma
Fondazione GONO Plus · 33 participants

📍 Italy

2025-523633-25-00 on CTIS ↗

Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)
Apellis Pharmaceuticals Inc. · 97 participants

📍 France · Portugal · Spain · Slovakia · Italy · Germany · Poland

2025-524448-36-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 14/07/2026

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc. · 337 participants

📍 Poland · Belgium · Norway · Sweden · Austria · Germany · Denmark · Netherlands · France · Italy · Spain

2025-525088-34-00 on CTIS ↗

Phase I Not possible to specify Authorised 14/07/2026

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Metastatic triple negative breast cancer
Universitaetsklinikum Aachen AöR · 18 participants

📍 Germany

2025-524027-49-00 on CTIS ↗

Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

Efficacy of oral bicarbonate versus placebo on the risk of assisted delivery in nulliparous women with prolonged labour (ProLabour): protocol fora randomized controlled trial

Prolonged labour
Region Hovedstaden · 1520 participants

📍 Denmark

2026-525682-45-00 on CTIS ↗

Phase II Immune System Diseases Authorised 13/07/2026

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

Antibody-mediated Kidney Disease
AstraZeneca AB · 17 participants

📍 France · Germany · Italy · Belgium · Poland · Spain

2025-524139-38-00 on CTIS ↗

Phase III Bacterial Infections and Mycoses Authorised 13/07/2026

Model-informed precision dosing for linezolid: a randomized clinical trial

Bacterial infection (pneumonia, skin or soft tissue infection) requiring treatment with linezolid in patients in intensive care unit
University Medical Center Hamburg-Eppendorf · 30 participants

📍 Germany

2024-517888-23-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 13/07/2026

Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL)

Relapsed/refractory Multiple myeloma
Polish Myeloma Consortium · 228 participants

📍 Poland

2025-525096-83-00 on CTIS ↗

Phase I/II Neoplasms Authorised 13/07/2026

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Multiple Myeloma (MM), Multiple Myeloma (MM)
AbbVie Deutschland GmbH & Co. KG · 88 participants

📍 Germany · Poland · Czechia · Belgium · France · Greece · Sweden · Portugal · Italy

2025-525105-20-00 on CTIS ↗

Phase II Immune System Diseases Authorised 13/07/2026

Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)

HIV-1 disease
Region Midtjylland · 60 participants

📍 Sweden · Norway · Denmark · Iceland

2025-523725-17-00 on CTIS ↗

Phase II Neoplasms Authorised 13/07/2026

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis
Recursion Pharmaceuticals Inc. · 20 participants

📍 Netherlands · Germany · Spain

2026-525282-50-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 13/07/2026

SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study

Cluster headache
Leids Universitair Medisch Centrum (LUMC) · 26 participants

📍 Netherlands

2025-523293-17-00 on CTIS ↗

Phase IV Reproductive and Urinary Physiological Phenomena Authorised 13/07/2026

Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.

Women with infertility and low ovarian reserve.
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA · 126 participants

📍 Spain

2026-526292-37-01 on CTIS ↗

Phase I Neoplasms Authorised 13/07/2026

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Relapsed or Refractory acute myeloid leukemia, Relapsed or Refractory chronic lymphocytic leukemia, Relapsed or Refractory higher-risk myelodysplastic syndromes, Relapsed or Refractory small lymphocytic lymphoma
Janssen Cilag International · 175 participants

📍 France · Spain · Germany · Denmark · Belgium

2026-525234-39-00 on CTIS ↗

Phase II Virus Diseases Authorised 13/07/2026

Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)

Long-term persistence of SARS-CoV-2
Goethe University Frankfurt · 24 participants

📍 Germany · Spain

2025-524442-10-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 10/07/2026

Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial

Myocardial fibrosis, Acute myocarditis
Spanish Society Of Cardiology · 152 participants

📍 Spain

2025-523092-33-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 10/07/2026

A Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 1b Study to Assess the Safety, Immunogenicity and Pharmacodynamics of TRB-001 in Early Idiopathic Parkinson’s Disease Patients

Parkinson's disease
Tridem Bioscience FlexCo · 18 participants

📍 Austria

2024-519123-14-00 on CTIS ↗

Phase II Female Urogenital Diseases and Pregnancy Complications Authorised 10/07/2026

Prospective trial of [18F]AlF-FAPI-74 for PET imaging of fibroblast activation protein in patients with endometriosis

endometriosis
UZ Leuven · 64 participants

📍 Belgium

2026-525272-25-00 on CTIS ↗

Phase I Cardiovascular Diseases Authorised 10/07/2026

A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Ranging Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTX611 in Healthy Adult Participants

Thromboembolic disorders
CRISPR Therapeutics AG · 48 participants

📍 Hungary

2026-526708-56-00 on CTIS ↗

Phase I/II Neoplasms Authorised 10/07/2026

EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma

Oncology
Region Hovedstaden · 39 participants

📍 Denmark

2026-525808-94-00 on CTIS ↗

Phase I Hormonal diseases Authorised 10/07/2026

A study to learn how a high-fat meal affects the way elinzanetant is taken up by the body in healthy women

Vasomotor symptoms as a sex hormone-dependent disorder in women and men
Bayer AG · 30 participants

📍 Germany

2026-525569-30-00 on CTIS ↗

Phase III Bacterial Infections and Mycoses Authorised 10/07/2026

Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial

Urinary tract infection or Pyelonephritis
Pohjois-Pohjanmaan hyvinvointialue · 250 participants

📍 Finland

2026-526444-13-01 on CTIS ↗

Phase II Neoplasms Authorised 09/07/2026

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
Elevar Therapeutics Inc. · 14 participants

📍 France · Spain

2025-523923-22-00 on CTIS ↗

Phase III Neoplasms Authorised 09/07/2026

AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

acute lymphoblastic leukemia in children and adolescents
Universitaetsklinikum Schleswig-Holstein AöR · 2250 participants

📍 Germany

2025-522190-11-01 on CTIS ↗

Phase II Neoplasms Authorised 09/07/2026

Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma

Pleural mesothelioma
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) · 42 participants

📍 Netherlands

2026-526036-38-00 on CTIS ↗

Phase IV Musculoskeletal Diseases Authorised 09/07/2026

Early switch to oral antibiotic therapy in vertebral osteomyelitis: a multicentre, open-label, randomised, active control, parallel group, non-inferiority trial (sWITCH-VO)

bone and joint infections
University Of Cologne · 280 participants

📍 Germany

2026-526270-17-00 on CTIS ↗

Phase II Immune System Diseases Authorised 08/07/2026

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
Argenx · 29 participants

📍 Greece · Italy · Germany · Belgium · Netherlands · Spain · Poland

2025-522939-33-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 08/07/2026

Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)

Multiple Sclerosis
Amsterdam UMC Stichting · 84 participants

📍 Netherlands

2026-525260-18-00 on CTIS ↗

Phase III Eye Diseases Authorised 08/07/2026

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

Allergic rhinitis/rhinoconjunctivitis due to house dust mites exposure
Probelte Pharma S.L. · 174 participants

📍 Spain

2026-526105-15-00 on CTIS ↗

Phase I Bacterial Infections and Mycoses Authorised 08/07/2026

Nasal application of Staphylococcus lugdunensis for decolonization of Staphylococcus aureus – a first-in-human proof-of-concept microbiome intervention study

Persistent or intermitting colonization of the nose with Staphylococcus aureus
Universitaetsklinikum Tuebingen AöR · 36 participants

📍 Germany

2024-514894-22-01 on CTIS ↗

Phase III Neoplasms Authorised 08/07/2026

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

Osteosarcoma
Institut Gustave Roussy · 508 participants

📍 Sweden · Poland · Denmark · Finland · Netherlands · Italy · France · Spain

2023-505575-69-01 on CTIS ↗

Phase II Nervous System Diseases Authorised 08/07/2026

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy

Narcolepsy
Eisai Limited · 51 participants

📍 Belgium · Italy · Spain · Germany

2025-523503-30-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 08/07/2026

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
Alnylam Pharmaceuticals Inc. · 5 participants

📍 Netherlands · Sweden · Germany

2025-524967-19-00 on CTIS ↗

Phase I Not possible to specify Authorised 08/07/2026

A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity

Healthy
Boehringer Ingelheim International GmbH · 44 participants

📍 Germany

2026-526307-30-00 on CTIS ↗

Phase I Virus Diseases Authorised 07/07/2026

A Trial to Evaluate the Safety and Drug Levels of Single and Multiple Oral Doses of AT-587 in Healthy Adults

Chronic hepatitis E virus (HEV) infection
Atea Pharmaceuticals Inc. · 62 participants

📍 Belgium

2026-526237-26-00 on CTIS ↗

Phase I Digestive System Diseases Authorised 07/07/2026

A clinical trial comparing how the body takes up budesonide from different forms of medicine when taken by mouth with or without food.

Acute eosinophilic esophagitis
Dr. Falk Pharma GmbH · 50 participants

📍 Sweden

2025-522686-29-00 on CTIS ↗

Phase I Bacterial Infections and Mycoses Authorised 07/07/2026

Phase I Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine

Gonorrhea
LimmaTech Biologics AG · 142 participants

📍 Germany

2026-526168-19-00 on CTIS ↗

Phase II Neoplasms Authorised 07/07/2026

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
Bristol-Myers Squibb Services Unlimited Company · 123 participants

📍 Belgium · Ireland · Germany · Norway · Italy · France · Spain

2025-524285-18-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 07/07/2026

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Grifols Therapeutics LLC · 20 participants

📍 Romania · Czechia · Poland

2025-522165-30-00 on CTIS ↗

Phase III Eye Diseases Authorised 07/07/2026

Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)

Cataract
Ntc S.r.l. · 536 participants

📍 Spain · Poland · Greece · Sweden · Italy

2026-525594-39-00 on CTIS ↗

Phase I Neoplasms Authorised 07/07/2026

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)

Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal Neoplasms Colorectal Neoplasms Esophageal Neoplasms Stomach Neoplasms Cholangiocarcinoma
Eli Lilly & Co. · 64 participants

📍 Germany · Netherlands

2025-521887-37-00 on CTIS ↗

Phase I/II Nutritional and Metabolic Diseases Authorised 07/07/2026

A PHASE 1/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFECTS ON CLINICAL OUTCOMES OF PEGTIBATINASE (TVT-058) ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH CYSTATHIONINE BETASYNTHASE-DEFICIENT HOMOCYSTINURIA (COMPOSE)

Classical Homocystinuria
Travere Therapeutics Switzerland GmbH, Travere Therapeutics Inc. · 6 participants

📍 France

2023-509074-31-00 on CTIS ↗

Phase III Neoplasms Authorised 07/07/2026

C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Pfizer Inc. · 91 participants

📍 France · Spain · Italy

2025-524717-86-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 07/07/2026

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

Fibrosing interstitial lung disease
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 20 participants

📍 Belgium · Greece · Germany · France · Finland · Spain · Czechia · Poland · Italy · Netherlands · Denmark · Portugal

2025-523369-32-00 on CTIS ↗

Phase III Neoplasms Authorised 07/07/2026

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

Multiple Myeloma
F. Hoffmann-La Roche AG · 133 participants

📍 France · Germany · Italy · Greece · Denmark · Czechia · Spain · Poland

2025-524028-23-00 on CTIS ↗

Phase III Neoplasms Authorised 06/07/2026

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
AbbVie Deutschland GmbH & Co. KG · 194 participants

📍 Portugal · Spain · France · Italy · Germany · Austria

2025-522563-15-00 on CTIS ↗

Phase III Neoplasms Authorised 06/07/2026

TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer

Patients with advanced or metastatic ER+ HER2- breast cancer
Unicancer · 526 participants

📍 France

2025-524213-84-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 06/07/2026

Macroleave: Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

bronchiectasis unrelated to cystic fibrosis
Centre Hospitalier Intercommunal Creteil · 185 participants

📍 France

2025-521493-33-00 on CTIS ↗

Phase II Surgical Procedures, Operative Authorised 06/07/2026

Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID

allogeneic haematopoietic stem cell transplant recipient, lung transplant
Hospices Civils De Lyon · 400 participants

📍 France

2025-524374-42-00 on CTIS ↗

Phase II Therapeutics Authorised 06/07/2026

Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)

Adult patients diagnosed with uncomplicated acute appendicitis
Assistance Publique Hopitaux De Paris · 560 participants

📍 France

2025-520783-17-01 on CTIS ↗

Phase II Neoplasms Authorised 06/07/2026

Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I

suspected malignant pulmonary disease (lung lesions and/or lymph nodes suspicious for lung cancer)
Universitair Medisch Centrum Groningen · 20 participants

📍 Netherlands

2024-510793-24-00 on CTIS ↗

Phase I Bacterial Infections and Mycoses Authorised 06/07/2026

A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.

Tuberculosis
Glaxosmithkline Research & Development Limited · 28 participants

📍 Spain

2026-525790-39-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 06/07/2026

Oral versus Intravenous Tranexamic Acid for Blood Loss Prevention in Off-Pump Coronary Artery Bypass Surgery: A Randomised Non-Inferiority Trial (TRANSCAB Study)

Coronary artery disease requiring off-pump coronary artery bypass surgery (OPCAB)
Sante et Prevoyance · 160 participants

📍 Belgium

2026-526581-24-01 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement · 613 participants

📍 Denmark · Sweden · Poland · Estonia · Portugal · Latvia · Spain · Hungary · Germany · Finland · Italy · Belgium · France

2024-518016-39-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement · 550 participants

📍 Germany · Romania · Greece · Norway · Netherlands · Poland · Lithuania · Czechia · Slovakia · Spain

2024-518213-25-00 on CTIS ↗

Phase I Neoplasms Authorised 06/07/2026

A Phase 1 Study of TORL-1-23 in Advanced Cancer

Advanced Cancer
Torl Biotherapeutics LLC · 12 participants

📍 Ireland

2024-517189-40-00 on CTIS ↗

Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 06/07/2026

iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy

Hypoxic-ischemic brain injury (HIBI) because of Perinatal Asphyxia (PA) or Perinatal arterial ischemic stroke (PAIS)
Universitair Medisch Centrum Utrecht · 162 participants

📍 Netherlands

2025-521506-17-01 on CTIS ↗

Phase IV Digestive System Diseases Authorised 06/07/2026

Efficacy, Safety, and Patient Satisfaction of Patient-Controlled Remimazolam Sedation in Outpatient Colonoscopy: A randomized controlled trial.

The trial will study sedation related to colonoscopy, therefore the trial is not concerned with the underlaying medical condition leading to the colonoscopy.
Region Hovedstaden · 1 participants

📍 Denmark

2026-525809-13-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 06/07/2026

The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease

Ischemic heart disease/Chronic coronary syndrome (Myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting)
Odense University Hospital · 7000 participants

📍 Denmark

2026-525442-30-00 on CTIS ↗

Phase IV Musculoskeletal Diseases Authorised 06/07/2026

Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference

Rheumatoid arthritis
Aalborg University Hospital, Aalborg University Hospital · 180 participants

📍 Denmark

2026-525221-21-01 on CTIS ↗

Phase I/II Neoplasms Authorised 03/07/2026

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors

Solid tumors
Larkspur Biosciences Inc. · 80 participants

📍 France

2026-525629-20-00 on CTIS ↗

Phase I Hemic and Lymphatic Diseases Authorised 03/07/2026

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis

End-Stage Kidney Disease (ESKD)
Regeneron Pharmaceuticals Inc. · 36 participants

📍 Belgium

2026-525844-14-00 on CTIS ↗

Phase II Mental Disorders Authorised 03/07/2026

The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)

Depression
Kobenhavns Universitet, Koebenhavns Universitet · 180 participants

📍 Denmark

2025-522961-31-01 on CTIS ↗

Phase II Neoplasms Authorised 03/07/2026

Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients

Acute lymphoblastic leukemia and lymphoma
Oslo University Hospital HF · 50 participants

📍 Norway

2025-522453-20-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 03/07/2026

Dual-agent fluorescence-guided surgery for colorectal liver metastases

Colorectal liver metastases
Leids Universitair Medisch Centrum (LUMC) · 39 participants

📍 Netherlands

2025-524755-31-00 on CTIS ↗

Phase II Psychological Phenomena Authorised 03/07/2026

A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder

Major Depressive Disorder
Ostfold Hospital Trust · 16 participants

📍 Norway

2024-520319-42-01 on CTIS ↗

Phase I Female Urogenital Diseases and Pregnancy Complications Authorised 03/07/2026

Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial

Bladder cancer, Bladder tumors, Urothelial cancer, Urothelial tumors
Region Sjaelland · 20 participants

📍 Denmark

2026-526388-39-00 on CTIS ↗

Phase II Neoplasms Authorised 03/07/2026

A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024

Advanced squamous non-small cell lung cancer
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica · 108 participants

📍 Italy

2024-517799-40-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 02/07/2026

Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment

myeloproliferative neoplasms
Centre Hospitalier Regional Et Universitaire De Brest · 50 participants

📍 France

2025-523921-17-00 on CTIS ↗

Phase II Diagnosis Authorised 02/07/2026

18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)

Patients (male or female) ≥18 years old with Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma), de novo or recurrence/persistence, With indeterminate pituitary MRI.
Centre Hospitalier Universitaire De Lille · 30 participants

📍 France

2025-523829-17-00 on CTIS ↗

Phase I Cardiovascular Diseases Authorised 02/07/2026

Bioequivalence Study of Dapagliflozin 10 mg

Not applicable (submitted trial is a BE study in healthy participants)
Vipharm S.A. · 40 participants

📍 Czechia

2026-526840-10-00 on CTIS ↗

Phase II Neoplasms Authorised 02/07/2026

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

Stage III Non Small Cell Lung Cancer
Intergroupe Francophone De Cancerologie Thoracique · 177 participants

📍 France

2025-522801-39-00 on CTIS ↗

Phase I Neoplasms Authorised 02/07/2026

Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial

Advanced thyroid cancer
Stichting Radboud University Medical Center · 10 participants

📍 Netherlands

2023-507214-28-00 on CTIS ↗

Phase III Mental Disorders Authorised 01/07/2026

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

First Episode Psychosis (FEP)
University Of Oxford · 156 participants

📍 Netherlands · Greece · Germany · Italy · Austria · Spain

2025-521929-32-01 on CTIS ↗

Phase I/II Neoplasms Authorised 01/07/2026

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ideaya Biosciences Inc. · 35 participants

📍 France · Spain

2025-523438-24-00 on CTIS ↗

Phase III Neoplasms Authorised 01/07/2026

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 206 participants

📍 Poland · Spain · Czechia · France · Italy · Germany · Greece

2025-523815-12-00 on CTIS ↗

Phase II Circulatory and Respiratory Physiological Phenomena Authorised 01/07/2026

High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.

Non-toxic acute cardiogenic shock
Oslo Universitetssykehus HF · 20 participants

📍 Norway

2025-523858-13-01 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 01/07/2026

A phase 1b trial to study the safety and effect of ZP9830 in patients with plaque psoriasis

Plaque Psoriasis
Zealand Pharma A/S · 32 participants

📍 Netherlands

2026-525220-15-00 on CTIS ↗

Phase I Immune System Diseases Authorised 01/07/2026

An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablet 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fed conditions.

Seasonal allergic rhinitis
Sun Pharmaceutical Industries Limited · 48 participants

📍 Romania

2026-525421-20-00 on CTIS ↗

Phase I Immune System Diseases Authorised 01/07/2026

An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study comparing Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablet USP 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fasting conditions.

Seasonal allergic rhinitis
Sun Pharmaceutical Industries Limited · 48 participants

📍 Romania

2026-525420-22-00 on CTIS ↗

Phase I/II Nervous System Diseases Authorised 01/07/2026

The headache- and migraine-inducing effects of apremilast in women with migraine without aura

Migraine without aura
Syddansk Universitet (University of Southern Denmark) · 14 participants

📍 Denmark

2026-525987-16-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 01/07/2026

A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)

Asthma
AstraZeneca AB · 35 participants

📍 Czechia · Poland · Hungary

2025-524914-26-00 on CTIS ↗

Phase I Immune System Diseases Authorised 01/07/2026

A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG · 19 participants

📍 Belgium · Netherlands · Spain · Germany · Italy

2025-523127-21-00 on CTIS ↗

Phase I Not possible to specify Authorised 01/07/2026

A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood

Healthy
Boehringer Ingelheim International GmbH · 16 participants

📍 Germany

2026-525549-60-00 on CTIS ↗

Phase III Neoplasms Authorised 01/07/2026

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S · 257 participants

📍 Finland · Belgium · Hungary · France · Denmark · Austria · Germany · Italy · Spain · Czechia · Norway · Poland

2025-522167-15-00 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 01/07/2026

C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity

chronic weight management and other weight-related co-morbidities
Pfizer Inc. · 57 participants

📍 Belgium

2026-526334-67-00 on CTIS ↗

Phase I Not possible to specify Authorised 30/06/2026

A study in healthy men to test how BI 1815368 is processed in the body

Healthy volunteers trial
Boehringer Ingelheim International GmbH · 8 participants

📍 Netherlands

2025-523949-10-00 on CTIS ↗

Phase IV Reproductive and Urinary Physiological Phenomena Authorised 30/06/2026

Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)

unexplained subfertillity, infertillity
Universitair Medisch Centrum Utrecht · 640 participants

📍 Netherlands

2026-525747-33-00 on CTIS ↗

Phase I Physiological processes Authorised 30/06/2026

Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women

No therapeutic indication in the current trial with healthy volunteers.
CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A. · 140 participants

📍 Bulgaria

2025-524775-23-00 on CTIS ↗

Phase I/II Neoplasms Authorised 30/06/2026

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

solid tumor
Krystal Biotech Inc. · 40 participants

📍 France · Spain

2025-522723-98-00 on CTIS ↗

Phase III Immune System Diseases Authorised 30/06/2026

Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)

Eosinophilic Disease
AstraZeneca AB · 7 participants

📍 Poland · Netherlands · France

2023-508533-14-00 on CTIS ↗

Phase II Neoplasms Authorised 30/06/2026

A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

metastatic pancreatic adecarcinoma
Theriva Biologics S.L. · 6 participants

📍 Spain

2026-525566-21-00 on CTIS ↗

Phase III Neoplasms Authorised 30/06/2026

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc. · 45 participants

📍 Spain · Belgium · France · Italy · Germany

2025-521971-29-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc. · 165 participants

📍 Greece · France · Italy · Belgium · Denmark · Germany · Poland · Czechia · Portugal · Austria · Spain · Romania

2025-521769-29-00 on CTIS ↗

Phase I/II Nervous System Diseases Authorised 30/06/2026

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

Dravet Syndrome
Ionis Pharmaceuticals Inc. · 12 participants

📍 Spain · France · Belgium · Portugal · Germany

2025-523835-20-00 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 30/06/2026

A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiation

Topical pain
Auxesis Pharma Holding AB (publ) · 12 participants

📍 Sweden

2026-526022-41-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 30/06/2026

Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci

Infectious endocarditis caused by Gram-positive cocci (staphylococci, enterococci, streptococci)
Friedrich-Schiller-Universitaet Jena · 166 participants

📍 Germany

2026-526149-91-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 30/06/2026

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

Participants with relapsed HRNB and participants with HRNB refractory to treatment The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent.
Renaissance Pharma Limited · 111 participants

📍 Spain · France · Denmark · Ireland · Germany

2025-524397-42-00 on CTIS ↗

Phase I Not possible to specify Authorised 30/06/2026

A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or without food in healthy adults

Not applicable, healthy volunteers
Dr. Falk Pharma GmbH · 32 participants

📍 Germany

2025-523778-17-00 on CTIS ↗

Phase I Not possible to specify Authorised 29/06/2026

A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers

Treatment of several inflammatory diseases, including inflammation-related fibrosis and autoinflammatory diseases
Allinky Biopharma S.L. · 42 participants

📍 Spain

2026-525830-49-00 on CTIS ↗

Phase III Skin and Connective Tissue Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 57 participants

📍 Germany · Romania · France · Bulgaria · Belgium · Spain · Poland · Greece · Italy · Czechia

2025-524855-30-00 on CTIS ↗

Phase III Immune System Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 54 participants

📍 Spain · Belgium · France · Germany · Slovakia · Romania · Bulgaria · Italy · Poland · Greece

2025-523871-44-00 on CTIS ↗

Phase III Neoplasms Authorised 29/06/2026

AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG · 243 participants

📍 Greece · Portugal · Germany · Belgium · Spain

2025-521712-19-00 on CTIS ↗

Phase III Not possible to specify Authorised 29/06/2026

Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial

Non-traumatic pain
Centre Hospitalier Regional Universitaire De Tours · 164 participants

📍 France

2025-525001-21-00 on CTIS ↗

Phase II Neoplasms Authorised 29/06/2026

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

Small Cell Lung Cancer
Pfizer Inc. · 15 participants

📍 France · Italy · Spain

2025-524686-24-00 on CTIS ↗

Phase II Mental Disorders Authorised 29/06/2026

Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA

Alcoholism
Institut National De La Sante Et De La Recherche Medicale · 60 participants

📍 France

2025-524148-36-00 on CTIS ↗

Phase IV Nutritional and Metabolic Diseases Authorised 29/06/2026

ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)

Obstructive sleep apnea syndrome, Obesity
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre · 345 participants

📍 Spain

2026-525500-10-00 on CTIS ↗

Phase II Neoplasms Authorised 29/06/2026

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

Non-small Cell Lung Cancer
AstraZeneca AB · 11 participants

📍 Spain · Germany

2025-523599-21-00 on CTIS ↗

Phase I/II Respiratory Tract Diseases Authorised 29/06/2026

PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER

Non small cell lung cancer
Radboud universitair medisch centrum Stichting · 40 participants

📍 Netherlands · Germany

2025-524791-30-00 on CTIS ↗

Phase I/II Neoplasms Authorised 29/06/2026

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

Solid Tumors
Revolution Medicines Inc. · 252 participants

📍 France · Poland · Ireland · Spain · Greece · Germany · Italy · Sweden · Belgium

2025-524623-50-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 29/06/2026

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

Community- acquired pneumonia related sepsis with evidence of Sepsis Induced Immunoparalysis SII
Elliniko Institouto Meletis Tis Sipsis · 252 participants

📍 Greece

2025-525058-20-00 on CTIS ↗

Phase I Diagnosis Authorised 29/06/2026

LAFOV-Lung PET

Investigation in healthy volunteers
Medical University Of Vienna · 41 participants

📍 Austria

2026-525834-45-00 on CTIS ↗

Phase II Immune System Diseases Authorised 29/06/2026

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Mediar Therapeutics Inc. · 36 participants

📍 Netherlands · Romania · Poland · France · Italy · Spain

2025-523288-39-00 on CTIS ↗

Phase I Neoplasms Authorised 29/06/2026

First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor

Glioblastoma
Ygion Biomedical GmbH · 15 participants

📍 Austria

2025-524299-44-00 on CTIS ↗

Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 29/06/2026

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

Non-Muscle Invasive Papillary Bladder Cancer
Hamlet BioPharma AB · 169 participants

📍 Czechia

2026-525531-16-00 on CTIS ↗

Phase IV Mental Disorders Authorised 29/06/2026

Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)

Major Depressive Disorder
Region Hovedstaden · 106 participants

📍 Denmark

2026-526314-90-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 28/06/2026

Self-Assessment Method for Statin side-effects Or Nocebo 2

Cardiovascular diseases
Copenhagen University Hospital, Region Hovedstaden · 160 participants

📍 Denmark

2025-524955-30-01 on CTIS ↗

Phase III Neoplasms Authorised 26/06/2026

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

Pancreatic Ductal Adenocarcinoma
Incyte Corp. · 239 participants

📍 Poland · Italy · Netherlands · Sweden · Denmark · Finland · Spain · France · Germany · Belgium · Norway · Austria

2025-525009-18-00 on CTIS ↗

Phase I Neoplasms Authorised 26/06/2026

A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb Services Unlimited Company · 22 participants

📍 France

2024-513987-24-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 26/06/2026

Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).

Coronary artery disease, Atrial fibrillation
UZ Leuven · 988 participants

📍 Belgium

2025-525121-13-00 on CTIS ↗

Phase IV Hormonal diseases Authorised 26/06/2026

Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.

Advanced thyroid carcinoma. Post-thyroidectomy hypothyroidism.
Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l. · 110 participants

📍 Italy

2026-526113-28-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 26/06/2026

Three-part PK and PD study of AXN-027

Chronic pain, refractory epilepsy, and other neurological disorders of excitation/inhibition (E/I) imbalance within neuronal circuits.
Axonis Therapeutics Inc. · 64 participants

📍 Netherlands

2025-524019-35-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 26/06/2026

Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy
Region Skane · 40 participants

📍 Sweden

2025-524722-17-00 on CTIS ↗

Phase II Disorders of Environmental Origin Authorised 26/06/2026

“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.

IgE-mediated respiratory allergic disease due to the allergen whose extract is to be standardized, DPT and DF.
Probelte Pharma S.L. · 30 participants

📍 Spain

2026-525628-13-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 26/06/2026

A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants with Solid and Hematologic Cancers (ROXI-CAT-II)

Cancer Associated Thrombosis
Regeneron Pharmaceuticals Inc. · 164 participants

📍 Bulgaria · Romania

2024-519299-16-00 on CTIS ↗

Phase I Mental Disorders Authorised 26/06/2026

Skin irritation and sensitization trial

The intended indication is for the treatment of major depressive disorder.
CCDRD Cooperative Clinical Drug Research and Development AG, Corium Innovations Inc. · 230 participants

📍 Bulgaria

2026-525269-34-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 26/06/2026

Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

Atrial Fibrillation
Universitaetsspital Basel · 1 participants

📍 Germany

2024-516033-12-00 on CTIS ↗

Phase IV Hemic and Lymphatic Diseases Authorised 26/06/2026

Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice

Adult with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
Uniwersytet Medyczny W Lublinie · 36 participants

📍 Poland

2025-524795-35-00 on CTIS ↗

Phase III Therapeutics Authorised 26/06/2026

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial

Patients after the first year following liver transplantation
Medizinische Hochschule Hannover · 150 participants

📍 Germany

2025-524312-11-00 on CTIS ↗

Phase IV Hemic and Lymphatic Diseases Authorised 25/06/2026

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol

Haematological diseases; any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs.
Region Hovedstaden · 200 participants

📍 Denmark

2026-525658-13-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 25/06/2026

Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease

parkinson's disease
Region Hovedstaden · 22 participants

📍 Denmark

2026-526465-18-00 on CTIS ↗

Phase I Immune system processes Authorised 25/06/2026

A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease

B-cell–mediated autoimmune diseases
Oblenio Bio Inc. · 45 participants

📍 Germany

2026-525621-20-00 on CTIS ↗

Phase I Immune System Diseases Authorised 25/06/2026

Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis

Rheumatoid Arthritis
Jade Biosciences Inc. · 24 participants

📍 Romania · Bulgaria · Germany

2025-524746-96-00 on CTIS ↗

Phase II Eye Diseases Authorised 25/06/2026

An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

Geographic atrophy secondary to age-related macular degeneration
PulseSight Therapeutics · 24 participants

📍 France

2025-525008-12-00 on CTIS ↗

Phase IV Diagnosis Authorised 25/06/2026

ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment

prostate cancer
Centre Hospitalier Universitaire De Toulouse · 30 participants

📍 France

2026-525181-22-00 on CTIS ↗

Phase III Immune System Diseases Authorised 24/06/2026

A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS

Multiple Sclerosis
F. Hoffmann-La Roche AG · 54 participants

📍 Spain · France · Poland · Italy

2025-523726-40-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 24/06/2026

Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial

Serious, chronic, life-limiting disease
Region Skane · 40 participants

📍 Sweden

2026-525838-32-00 on CTIS ↗

Phase III Mental Disorders Authorised 24/06/2026

Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)

Post-traumatic stress disorder (PTSD)
Centre Hospitalier Universitaire De Toulouse · 76 participants

📍 France

2025-523107-30-01 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 24/06/2026

A single and multiple dose trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of ZP6590

Weight management
Zealand Pharma A/S · 88 participants

📍 Germany

2026-525978-19-00 on CTIS ↗

Phase I Anesthesia and Analgesia Authorised 24/06/2026

Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel

Bioequivalence, musculoskeletal pain pain
Fysioline Oy · 34 participants

📍 Finland

2026-526434-21-00 on CTIS ↗

Phase I Immune System Diseases Authorised 24/06/2026

THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom

IPEX syndrome is a primary immunodeficiency caused by hemizygous mutations in the gene FOXP3, which encodes an essential transcription factor required to maintain immunological tolerance by thymus-derived regulatory T (Treg) cells., Patients affected by IPEX syndrome, proven by molecular diagnosis, with any active autoimmune complications or controlled under immunosuppressive therapy can be enrolled in this trial.
Assistance Publique Hopitaux De Paris · 5 participants

📍 France

2025-523305-15-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 23/06/2026

ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis

liver cirrhosis
Amsterdam UMC Stichting · 634 participants

📍 Netherlands

2026-526167-38-00 on CTIS ↗

Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 23/06/2026

The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial

infertility
Santiago Dexeus Font Fundacio Privada · 240 participants

📍 Spain

2025-524761-25-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 23/06/2026

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement · 41 participants

📍 Poland · Spain · France · Netherlands · Germany

2025-523403-29-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 23/06/2026

Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone

Small for gestational age (SGA) and idiopathic short stature (ISS)
Schneider Children's Medical Center Of Israel · 95 participants

📍 Greece · Poland · France · Czechia

2025-523832-38-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 23/06/2026

USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.

Hypoxemic episodes in patients undergoing gastroscopy, colonoscopy, or oral endoscopic ultrasound under deep sedation with oxygen therapy administration.
Hospital Universitario Rio Hortega · 326 participants

📍 Spain

2026-525766-21-01 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 23/06/2026

ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial

patients with influenza-induced acute hypoxemic respiratory failure
Centre Hospital Region Metz Thionville · 544 participants

📍 France

2025-524976-40-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 23/06/2026

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis (RRMS)
F. Hoffmann-La Roche AG · 9 participants

📍 Poland · Germany · France

2025-524164-37-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 23/06/2026

A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).

Heriditary spastic paraplegia (SPG50)
Rigshospitalet, Elpida Therapeutics SPC · 2 participants

📍 Denmark

2025-524481-15-00 on CTIS ↗

Phase IV Musculoskeletal Diseases Authorised 23/06/2026

Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial

Juvenil Idiopatic Arthritis
Oslo Universitetssykehus HF · 90 participants

📍 Norway

2026-525611-13-00 on CTIS ↗

Phase III Male Urogenital Diseases Authorised 23/06/2026

SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon®

Benign prostatic hypertrophy
Azienda Ospedaliero Universitaria Careggi, University Of Florence · 410 participants

📍 Italy

2025-525123-27-00 on CTIS ↗

Phase III Neoplasms Authorised 23/06/2026

A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer

Non-Resectable Locally Advanced Pancreatic Cancer (LAPC)
Silexion Therapeutics Ltd. · 10 participants

📍 Germany

2025-525157-39-00 on CTIS ↗

Phase II Neoplasms Authorised 23/06/2026

Efficacy of asciminib in chronic phase CML patients with T315l mutations

Chronic Myeloid Leukemia
Friedrich-Schiller-Universitaet Jena · 50 participants

📍 Germany

2025-523491-23-00 on CTIS ↗

Phase III Immune System Diseases Authorised 22/06/2026

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Hereditary Angioedema
Adarx Pharmaceuticals Inc. · 45 participants

📍 Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia

2025-521353-16-00 on CTIS ↗

Phase I/II Neoplasms Authorised 22/06/2026

Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy

HCC – Hepatocellular Carcinoma
Centr Georges Francois Leclerc · 30 participants

📍 France

2026-526324-48-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 22/06/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC · 467 participants

📍 Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece

2025-524322-18-00 on CTIS ↗

Phase II Neoplasms Authorised 22/06/2026

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc. · 88 participants

📍 Germany · France · Poland · Italy · Spain

2025-524488-18-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 22/06/2026

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

Colitis ulcerative
Merck Sharp & Dohme LLC · 44 participants

📍 Italy · Greece · Netherlands · Poland · Germany · France

2025-523479-49-00 on CTIS ↗

Phase II Neoplasms Authorised 22/06/2026

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Verastem Inc. · 4 participants

📍 France

2025-524713-88-00 on CTIS ↗

Phase I/II Musculoskeletal Diseases Authorised 22/06/2026

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis
Trace Neuroscience Inc. · 20 participants

📍 Germany · Netherlands

2025-523111-11-00 on CTIS ↗

Phase IV Musculoskeletal Diseases Authorised 22/06/2026

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

Metachromatic leukodystrophy
Orchard Therapeutics (Europe) Limited · 29 participants

📍 Netherlands · Germany · Italy · Sweden · France

2025-522275-28-00 on CTIS ↗

Phase I Neoplasms Authorised 22/06/2026

Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation

Clonal Cytopenia of Undetermined Significance with SF3B1 mutation, Low-Risk Myelodysplastic Syndrome with SF3B1 mutation
Regeneron Pharmaceuticals Inc. · 15 participants

📍 Belgium

2026-525464-18-00 on CTIS ↗

Phase II Mental Disorders Authorised 22/06/2026

Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study

Posttraumatic stress disorder
ARQ National Psychotrauma Centrum · 12 participants

📍 Netherlands

2025-521488-11-00 on CTIS ↗

Phase II Bacterial Infections and Mycoses Authorised 22/06/2026

Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial

Fracture-Related Infection
Amsterdam UMC Stichting · 50 participants

📍 Netherlands

2026-525871-24-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 22/06/2026

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc. · 69 participants

📍 Spain · Italy · France

2025-522587-33-00 on CTIS ↗

Phase II Eye Diseases Authorised 22/06/2026

Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study

Retinopathy of prematurity
St. Olavs Hospital HF · 33 participants

📍 Norway

2023-507975-23-01 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 22/06/2026

Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events

Coronary atherosclerosis
Daiichi Sankyo Europe GmbH · 103 participants

📍 Italy · Spain · Germany

2025-524625-41-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 22/06/2026

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

Osteogenesis Imperfecta
Angitia Inc. Ltd. · 40 participants

📍 Netherlands · France · Denmark

2025-522951-24-00 on CTIS ↗

Phase I Neoplasms Authorised 22/06/2026

Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma

Stage IIB/C, Stage III, or Stage IV Melanoma
Biocon Biologics UK PLC · 43 participants

📍 Spain · Romania

2025-525158-20-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 22/06/2026

A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee

Osteoarthritis of the knee
Latigo Biotherapeutics Inc. · 180 participants

📍 Denmark

2026-525966-22-00 on CTIS ↗

Phase III Immune System Diseases Authorised 19/06/2026

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

Systemic Sclerosis
Celgene Corp. · 33 participants

📍 Spain · Germany · France · Italy

2025-524337-11-00 on CTIS ↗

Phase I Immune System Diseases Authorised 19/06/2026

A Phase 1 first-in-human study to evaluate SAR448272 in adult participants

healthy volunteers, immunological diseases
Sanofi-Aventis Recherche & Developpement · 147 participants

📍 Germany

2026-526014-87-00 on CTIS ↗

Phase IV Nutritional and Metabolic Diseases Authorised 19/06/2026

Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i

Type 2 diabetes
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 60 participants

📍 Spain

2025-523374-17-03 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 19/06/2026

Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)

Marginal Zone Lymphoma
Universitaetsklinikum Ulm AöR · 53 participants

📍 Germany

2025-524879-23-00 on CTIS ↗

Phase IV Digestive System Diseases Authorised 19/06/2026

Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.

Post-ERCP Pancreatitis
Amsterdam UMC Stichting · 520 participants

📍 Netherlands

2025-522900-26-00 on CTIS ↗

Phase I Not possible to specify Authorised 19/06/2026

A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity

Cardiometabolic
Novo Nordisk A/S · 128 participants

📍 Netherlands

2026-525179-26-00 on CTIS ↗

Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 18/06/2026

Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product

Ornithine Transcarbamylase Deficiency (OTC)
Iecure Inc. · 3 participants

📍 Spain · France

2024-514190-21-00 on CTIS ↗

Phase I Virus Diseases Authorised 18/06/2026

A first study in healthy volunteers to examine the safety and tolerability of convalescent plasma given through the nose, as well as the duration of its presence in the nose

Healthy volunteers
Rode Kruis-Vlaanderen · 104 participants

📍 Belgium

2025-525085-29-00 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 18/06/2026

A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients

Atopic Dermatitis
Pfizer Inc. · 19 participants

📍 Poland

2025-524150-34-00 on CTIS ↗

Phase I Male Urogenital Diseases Authorised 18/06/2026

A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.

High-risk non-muscle invasive bladder cancer (NMIBC)
Laboratorio Reig Jofre S.A. · 44 participants

📍 Spain

2026-525897-20-00 on CTIS ↗

Phase III Neoplasms Authorised 18/06/2026

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO

Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma
Fondazione GONO G.I. · 212 participants

📍 Spain · Germany · Italy

2025-524048-36-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 18/06/2026

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR · 110 participants

📍 Spain · Germany · Italy · Sweden · France · Luxembourg

2024-513496-40-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 17/06/2026

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

Demyelinating diseases
Medizinische Hochschule Hannover · 116 participants

📍 Germany · Austria

2025-523654-13-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 17/06/2026

Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial

Osteoporotic Fracture
University Hospital Of Clermont-Ferrand · 30 participants

📍 France

2025-524889-25-00 on CTIS ↗

Phase IV Digestive System Diseases Authorised 17/06/2026

STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial

ulcerative colitis
Centre Hospitalier Regional De Marseille · 224 participants

📍 France

2026-525643-32-00 on CTIS ↗

Phase I Neoplasms Authorised 17/06/2026

A Study to Learn About How Different Forms of Study Medicine Prifetrastat are Taken Up Into the Blood in Healthy Adults

Locally advanced or metastatic ER+/HER2- breast cancer
Pfizer Inc. · 32 participants

📍 Belgium

2026-526038-26-00 on CTIS ↗

Phase I Neoplasms Authorised 17/06/2026

Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer

Other Solid Tumors Associated with Nectin-4 Expression, Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer
Rondo Therapeutics Inc. · 34 participants

📍 Spain

2025-524687-38-00 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 17/06/2026

A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients

Phenylketonuria
Mipsalus ApS · 7 participants

📍 Denmark

2024-519121-38-01 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 17/06/2026

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company · 318 participants

📍 Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany

2025-522373-10-00 on CTIS ↗

Phase II Skin and Connective Tissue Diseases Authorised 17/06/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period

Systemic sclerosis
Galderma S.A. · 56 participants

📍 Poland · Italy · Bulgaria · France · Greece · Spain · Croatia

2025-522294-11-00 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 16/06/2026

A First‑in‑Human Phase 1 Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

Healthy volunteers
Arcus Biosciences Inc. · 130 participants

📍 Netherlands

2026-526279-52-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 16/06/2026

RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer

Stage I non-small cell lung cancer
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting · 30 participants

📍 Netherlands

2025-524305-32-00 on CTIS ↗

Phase I Neoplasms Authorised 16/06/2026

Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer

Solid Tumors
Theras Inc. · 2999997 participants

📍 Spain · Italy · France

2025-524690-16-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 16/06/2026

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Duchenne Muscular Dystrophy
Entrada Therapeutics Inc. · 56 participants

📍 Belgium · Italy · Netherlands · Spain

2025-525124-10-00 on CTIS ↗

Phase I Neoplasms Authorised 16/06/2026

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Hematological malignancies, Advanced solid tumors
Incyte Corp. · 150 participants

📍 Italy · Belgium · Denmark

2025-523130-11-00 on CTIS ↗

Phase III Neoplasms Authorised 16/06/2026

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2
AstraZeneca AB · 516 participants

📍 France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands

2024-519787-40-00 on CTIS ↗

Phase I/II Neoplasms Authorised 16/06/2026

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

Metastatic Prostate Cancer
AstraZeneca AB · 45 participants

📍 Belgium · Spain · Poland · Italy · Netherlands

2025-520626-37-00 on CTIS ↗

Phase III Neoplasms Authorised 16/06/2026

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Stage I NSCLC
Merck Sharp & Dohme LLC · 283 participants

📍 Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain

2025-522643-18-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 16/06/2026

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc. · 228 participants

📍 Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania

2025-524640-35-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 15/06/2026

Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms

Heart failure
Centre Hospitalier Universitaire De Montpellier · 1050 participants

📍 France

2025-524344-35-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 15/06/2026

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement · 177 participants

📍 France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain

2024-511296-15-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 15/06/2026

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Limb Girdle Muscular Dystrophy (LGMD) Type 2I
ML Bio Solutions Inc. · 35 participants

📍 Germany · Denmark · Netherlands · Italy · Norway

2025-524371-23-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 15/06/2026

A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed.

Vascular malfomation
Oslo University Hospital HF · 20 participants

📍 Norway

2024-511937-37-01 on CTIS ↗

Phase II Neoplasms Authorised 15/06/2026

A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy

Multiple myeloma (RRMM)
Odense University Hospital · 50 participants

📍 Finland · Denmark · Estonia · Norway

2025-522114-23-00 on CTIS ↗

Phase IV Immune System Diseases Authorised 15/06/2026

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)
Swedish Orphan Biovitrum AB (publ) · 69 participants

📍 France · Italy · Spain · Germany

2025-524487-37-00 on CTIS ↗

Phase II Diagnosis Authorised 13/06/2026

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

Transthyretin cardiac amyloidosis
Centre Hospitalier Universitaire De Nantes · 40 participants

📍 France

2025-523616-36-00 on CTIS ↗

Phase III Neoplasms Authorised 12/06/2026

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation
Merck Sharp & Dohme LLC · 88 participants

📍 Italy · Netherlands · France · Germany · Spain · Poland · Greece

2025-522038-29-00 on CTIS ↗

Phase I Not possible to specify Authorised 12/06/2026

A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.

Not applicable for phase I study
Antabio · 40 participants

📍 France

2026-526411-11-00 on CTIS ↗

Phase III Neoplasms Authorised 12/06/2026

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed/refractory B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC · 109 participants

📍 Greece · Netherlands · Sweden · France · Italy · Spain · Denmark

2025-522267-15-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 210 participants

📍 Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria

2025-523674-16-00 on CTIS ↗

Phase IV Musculoskeletal Diseases Authorised 12/06/2026

BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial

Fatigue in rheumatoid arthritis patients
Odense University Hospital · 150 participants

📍 Denmark

2024-519268-41-00 on CTIS ↗

Phase I Reproductive and Urinary Physiological Phenomena Authorised 12/06/2026

Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.

Healthy subjects
Pevisal Group Farmaceutici S.r.l. · 24 participants

📍 Czechia

2025-524871-22-00 on CTIS ↗

Phase II Neoplasms Authorised 12/06/2026

A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2

patients with unrestectable hepatocellular carcinoma (SLIDE-HCC)
IRCCS Istituto Nazionale Tumori Fondazione Pascale · 56 participants

📍 Italy

2025-521608-23-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 11/06/2026

J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD01 - Crohn Disease
Eli Lilly & Co. · 37 participants

📍 Italy · Germany · Hungary · Poland · Belgium

2025-524112-11-00 on CTIS ↗

Phase I/II Immune System Diseases Authorised 11/06/2026

Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.

Refractory Lupus Nephritis
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz · 10 participants

📍 Spain

2025-522449-23-00 on CTIS ↗

Phase III Otorhinolaryngologic Diseases Authorised 11/06/2026

Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) – Protocol OMCOS

chronic suppurative otitis media (CSOM)
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre · 88 participants

📍 Spain

2026-525540-15-00 on CTIS ↗

Phase II Neoplasms Authorised 11/06/2026

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ, and esophageal adenocarcinomas
Gilead Sciences Inc. · 45 participants

📍 Spain · France

2025-524095-27-00 on CTIS ↗

Phase IV Digestive System Diseases Authorised 11/06/2026

Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed, moderate-to-severe Crohn’s disease: A 52-week, multicenter, open-label, randomized controlled trial

Crohn’s disease
Universitaetsklinikum Schleswig-Holstein AöR · 320 participants

📍 Germany

2026-525191-26-00 on CTIS ↗

Phase IV Digestive System Diseases Authorised 11/06/2026

Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease

Patients with celiac disease
Venter Pharma S.L. · 42 participants

📍 Spain

2026-525518-70-00 on CTIS ↗

Phase I/II Not possible to specify Authorised 10/06/2026

ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Assistance Publique Hopitaux De Paris · 36 participants

📍 France

2025-524728-22-01 on CTIS ↗

Phase III Neoplasms Authorised 10/06/2026

First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)

Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resected
Institut Gustave Roussy · 504 participants

📍 France

2025-523593-16-00 on CTIS ↗

Phase III Bacterial Infections and Mycoses Authorised 10/06/2026

A Phase 3 prospective, randomized, multicenter, active-controlled study to evaluate the efficacy and safety of BV100 plus low-dose polymyxin B compared with colistin plus high-dose ampicillin/sulbactam in the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex

Hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex
Bioversys S.A.S. · 58 participants

📍 Greece · Croatia

2025-524092-23-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 10/06/2026

J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Eli Lilly & Co. · 104 participants

📍 Latvia · Portugal · Greece · France · Czechia · Italy · Poland · Slovakia · Hungary · Croatia · Lithuania

2025-524404-29-00 on CTIS ↗

Phase I Neoplasms Authorised 10/06/2026

A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors

Patients with metastatic PDAC, NSCLC, HR+/HER2- ductal and lobular BC, TNBC, CRC or STS.
Novartis Pharma AG · 22 participants

📍 Denmark

2025-523665-24-00 on CTIS ↗

Phase III Neoplasms Authorised 09/06/2026

Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)

Advanced lymphoid leukemia
Institut De Recherches Internationales Servier IRIS · 1 participants

📍 France

2026-526212-37-00 on CTIS ↗

Phase III Neoplasms Authorised 09/06/2026

A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.

Follicular Lymphoma
Merck Sharp & Dohme LLC · 9 participants

📍 France · Spain · Greece

2025-522777-10-00 on CTIS ↗

Phase I Neoplasms Authorised 09/06/2026

A trial in healthy participants to find out how long JNJ-101556143 stays in and acts on the body when administered as different formulations and under different food conditions

Prostate Cancer
Janssen Cilag International · 48 participants

📍 Belgium

2026-526263-38-00 on CTIS ↗

Phase IV Immune System Diseases Authorised 09/06/2026

DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial

Rheumatoid arthritis
Sint Maartenskliniek Stichting · 202 participants

📍 Netherlands

2026-525316-33-00 on CTIS ↗

Phase III Hemic and Lymphatic Diseases Authorised 09/06/2026

Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent)

Newly diagnosed Multiple Myeloma in patients eligible for stem cell transplantation
Universitaetsklinikum Heidelberg AöR · 399 participants

📍 Germany

2025-523990-40-00 on CTIS ↗

Phase I/II Neoplasms Authorised 09/06/2026

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

Advanced KRAS G12D-Mutant Solid Tumors
Verastem Inc. · 210 participants

📍 Italy · France · Germany · Belgium · Spain · Netherlands

2025-523432-39-01 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 09/06/2026

Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis

Bronchiectasis
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau · 160 participants

📍 Spain

2025-524454-34-00 on CTIS ↗

Phase III Hemic and Lymphatic Diseases Authorised 08/06/2026

Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial

Congenital hemophilia A (HA), Synovitis
GWT-Tud GmbH · 60 participants

📍 Austria · Germany

2025-523896-44-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 08/06/2026

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)

Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc. · 496 participants

📍 Norway · Czechia · Portugal · Austria · Poland · France · Spain

2025-522176-86-01 on CTIS ↗

Phase I/II Neoplasms Authorised 08/06/2026

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

Small cell lung cancer extensive stage
Merck Sharp & Dohme LLC · 79 participants

📍 Germany · Poland · Greece · Italy · France · Spain

2025-521032-11-00 on CTIS ↗

Phase I Mental Disorders Authorised 08/06/2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers

Schizophrenia
Syremis Therapeutics Ltd. · 280 participants

📍 France

2026-525700-10-00 on CTIS ↗

Phase III Hemic and Lymphatic Diseases Authorised 08/06/2026

HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia RED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL

Relapsed or refractory chronic lymphocytic leukemia, Relapsed or refractory small lymphocytic lymphoma
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting · 456 participants

📍 Netherlands

2025-524283-38-00 on CTIS ↗

Phase IV Nutritional and Metabolic Diseases Authorised 08/06/2026

A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum

obesity
UZ Leuven · 96 participants

📍 Belgium

2026-526016-36-00 on CTIS ↗

Phase II Skin and Connective Tissue Diseases Authorised 08/06/2026

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

Nonsegmental vitiligo
Novartis Pharma AG · 80 participants

📍 Germany · Spain · Netherlands · France · Italy

2025-522301-37-00 on CTIS ↗

Phase II Immune System Diseases Authorised 08/06/2026

J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

Alopecia Areata
Eli Lilly & Co. · 14 participants

📍 Poland · Netherlands

2025-524727-41-00 on CTIS ↗

Phase III Bacterial Infections and Mycoses Authorised 08/06/2026

PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP – TRIAL)

ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus · 500 participants

📍 Spain

2026-525355-93-00 on CTIS ↗

Phase II Neoplasms Authorised 08/06/2026

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).

Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Gilead Sciences Inc. · 94 participants

📍 Spain · Italy · France

2025-523984-39-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 08/06/2026

Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?

Laparoscopic cholecystectomy
Fundacion Biomedica Galicia Sur · 66 participants

📍 Spain

2026-525783-18-00 on CTIS ↗

Phase I/II Respiratory Tract Diseases Authorised 08/06/2026

TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency

Lung and/or Liver Disease Associated with Alpha-1 Antitrypsin Deficiency (AATD)
Tessera Therapeutics Inc. · 25 participants

📍 Ireland · Sweden · Netherlands

2025-523497-16-00 on CTIS ↗

Phase I/II Neoplasms Authorised 08/06/2026

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)

Advanced or metastatic histologically confirmed soft tissue sarcoma (STS) in adult patients who are not candidates for curative treatment.
Medica Scientia Innovation Research S.L. · 278 participants

📍 Spain

2025-525144-18-00 on CTIS ↗

Phase III Neoplasms Authorised 08/06/2026

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC)
Zai Lab (US) LLC · 234 participants

📍 Belgium · Czechia · Germany · Denmark · Greece · Netherlands · Poland · Spain · Austria · Italy · France

2025-522818-23-00 on CTIS ↗

Phase II Immune System Diseases Authorised 08/06/2026

REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)

Immune Aging, Chronic inflammation
Radboud universitair medisch centrum Stichting · 150 participants

📍 Netherlands

2026-526084-38-00 on CTIS ↗

Phase II Neoplasms Authorised 08/06/2026

Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.

Symptomatic bone metastases from breast cancer
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone · 50 participants

📍 Italy

2025-524208-31-00 on CTIS ↗

Phase II Therapeutics Authorised 08/06/2026

Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.

Parkinson's disease
Universidad Rey Juan Carlos · 40 participants

📍 Spain

2026-525701-12-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 08/06/2026

A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease

Congenital Heart Disease
Chiesi Farmaceutici S.p.A. · 48 participants

📍 Netherlands · Germany · Portugal · Austria

2025-523109-14-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 08/06/2026

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Pfizer Inc. · 318 participants

📍 Spain · Germany · Poland · Czechia · Greece · Italy · Bulgaria · France · Hungary

2024-518587-12-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 08/06/2026

A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy

Drug resistant epilepsy
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. · 36 participants

📍 Sweden

2026-525478-21-00 on CTIS ↗

Phase IV Nervous System Diseases Authorised 08/06/2026

OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab

Generalized Myasthenia Gravis
Alexion Pharmaceuticals Inc. · 15 participants

📍 Italy · Germany

2025-522555-26-00 on CTIS ↗

Phase IV Immune System Diseases Authorised 08/06/2026

PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

granulomatosis with polyangiitis and microscopic polyangiitis
Assistance Publique Hopitaux De Paris · 70 participants

📍 France

2025-522049-23-00 on CTIS ↗

Phase II Neoplasms Authorised 08/06/2026

An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases

Oral Squamous Cell Carcinoma with neck metastases, Oropharyngeal Squamous Cell Carcinoma
Rigshospitalet · 40 participants

📍 Denmark

2025-522845-23-00 on CTIS ↗

Phase IV Virus Diseases Authorised 08/06/2026

Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up

Prevention of measles, mumps, and rubella by vaccination
Rigshospitalet · 1000 participants

📍 Denmark

2026-526160-21-00 on CTIS ↗

Phase I Neoplasms Authorised 08/06/2026

A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation

adenocarcinoma of the colon or rectum
Bayer Consumer Care AG · 49 participants

📍 Finland · Spain · Sweden · Italy · Denmark · Netherlands · Belgium

2025-523648-11-00 on CTIS ↗

Phase I/II Neoplasms Authorised 08/06/2026

KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments

Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer; advanced solid tumors harboring the KRAS G12C mutation.
Novartis Pharma AG · 31 participants

📍 Spain · Italy · France · Denmark · Belgium

2025-523537-26-00 on CTIS ↗

Phase II Virus Diseases Authorised 08/06/2026

Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.

HIV-1 infection
Instituto De Salud Carlos III · 60 participants

📍 Spain

2025-524363-20-01 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 08/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 173 participants

📍 Belgium · Greece · Poland · France · Spain · Bulgaria · Italy · Germany · Austria · Netherlands

2025-523675-39-00 on CTIS ↗

Phase II Behavioral Disciplines and Activities Authorised 08/06/2026

Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)

alcohol dependence
Hospital Universitario 12 De Octubre · 118 participants

📍 Spain

2023-504439-42-03 on CTIS ↗

Phase III Anesthesia and Analgesia Authorised 05/06/2026

OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery

indication for pulmonary resection surgery (segmentectomy or lobectomy), video-assisted thoracoscopy or scheduled robot-assisted surgery.
Centre Hospitalier Universitaire De Rennes · 176 participants

📍 France

2025-524240-35-00 on CTIS ↗

Phase III Mental Disorders Authorised 05/06/2026

ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms

Alcohol use disorder, depressive symptoms
Centre Hospitalier Universitaire De Nimes · 172 participants

📍 France

2025-525069-65-00 on CTIS ↗

Phase III Neoplasms Authorised 05/06/2026

PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence

Participants with R0/R1 resected liver metastases from colorectal cancer (CRLM).
Unicancer · 272 participants

📍 France

2025-523913-27-00 on CTIS ↗

Phase IV Bacterial Infections and Mycoses Authorised 05/06/2026

ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis

Infection prophylaxis
Assistance Publique Hopitaux De Paris · 10 participants

📍 France

2025-521988-13-00 on CTIS ↗

Phase II Investigative Techniques Authorised 05/06/2026

Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy

Septic Coagulopathy
Les Hopitaux Universitaires De Strasbourg · 120 participants

📍 France

2025-523397-16-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 05/06/2026

BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)

Severe Asthma
Amsterdam UMC Stichting · 142 participants

📍 Netherlands

2025-524741-28-00 on CTIS ↗

Phase II Mental Disorders Authorised 05/06/2026

Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG

Schizophrenia spectrum disorder (SSD)
Region Oerebro Laen · 122 participants

📍 Sweden

2026-525324-26-00 on CTIS ↗

Phase III Eye Diseases Authorised 05/06/2026

A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 250 participants

📍 Austria · Slovakia · Portugal · Czechia · Hungary · Spain · France · Denmark · Italy · Croatia

2025-524894-17-00 on CTIS ↗

Phase IV Nutritional and Metabolic Diseases Authorised 05/06/2026

A randomised, double-blind, three parallel-group, placebo controlled superiority trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in iron deficient FRAIL elderly IndiviDuals with cardiovascular disease (FRAIL-ID trial)

Frailty with Iron Deficiency in Elderly Patients with Cardiovascular Disease
Wroclaw Medical University · 396 participants

📍 Poland

2025-521570-34-00 on CTIS ↗

Phase II Neoplasms Authorised 05/06/2026

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer

Gastric cancer
Varsinais-Suomen hyvinvointialue · 80 participants

📍 Finland

2026-526494-42-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 05/06/2026

A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

Multiple Sclerosis; Primary Progressive Multiple Sclerosis; non-active Secondary Progressive Multiple Sclerosis
Sundance Biosciences Inc. · 30 participants

📍 Finland

2026-525817-29-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 04/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Narcolepsy Type 2
Alkermes Inc. · 106 participants

📍 Spain · Netherlands · Belgium · Italy · France · Germany

2025-523912-35-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 04/06/2026

Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE

Incidental Subsegmental Pulmonary Embolism in cancer patients
Region Hovedstaden · 234 participants

📍 Denmark

2025-524110-28-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 04/06/2026

TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH

Aneurysmal subarachnoid hemorrhage
Centre Hospitalier Universitaire De Toulouse · 274 participants

📍 France

2023-509795-42-00 on CTIS ↗

Phase I/II Neoplasms Authorised 04/06/2026

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.

Patients with poor prognostic ovarian cancers based on the tumor primary chemonsensitivity and incomplete debulking surgery.
Asso De Recherche Cancers Gynecologiques · 43 participants

📍 France

2025-524232-20-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 04/06/2026

Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions

Not applicable (submitted trial is a bioavailability trial in healthy participants).
Laboratorios Cinfa S.A. · 36 participants

📍 Czechia

2026-525780-41-00 on CTIS ↗

Phase I Diagnosis Authorised 04/06/2026

T cell imaging in kidney transplantation (TIK)

Renal allograft rejection
Radboud universitair medisch centrum Stichting · 9 participants

📍 Netherlands

2025-522490-11-00 on CTIS ↗

Phase I/II Respiratory Tract Diseases Authorised 04/06/2026

A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults

Respiratory Syncytial Virus Infections+Metapneumovirus
GlaxoSmithKline Biologicals · 464 participants

📍 Belgium

2025-524456-58-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 04/06/2026

Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries

Traumatic brain injury
Astrocyte Pharmaceuticals Inc. · 48 participants

📍 Netherlands

2026-525554-11-00 on CTIS ↗

Phase III Diagnosis Authorised 03/06/2026

Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial

Cardiovascular disease
Vaestra Goetalandsregionen · 40000 participants

📍 Sweden

2024-518706-41-01 on CTIS ↗

Phase I/II Nervous System Diseases Authorised 03/06/2026

A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.

Amyotrofic Lateral Sclerosis (ALS)
Nura Bio Inc. · 46 participants

📍 Poland · Netherlands · Italy · Spain

2025-523939-18-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 03/06/2026

Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE)

Parkinson's Disease
Karolinska University Hospital · 98 participants

📍 Sweden

2026-525906-37-00 on CTIS ↗

Phase III Eye Diseases Authorised 03/06/2026

A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 130 participants

📍 Spain · Poland · Estonia · Latvia · Germany

2025-524575-22-00 on CTIS ↗

Phase I/II Neoplasms Authorised 02/06/2026

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma Inc. · 180 participants

📍 Spain · Ireland · Italy · France · Romania

2025-523590-42-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 02/06/2026

A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)

Multiple Sclerosis
Region Stockholm – SLSO · 60 participants

📍 Sweden

2025-523892-50-00 on CTIS ↗

Phase II Otorhinolaryngologic Diseases Authorised 02/06/2026

Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers

patients with head and neck squamous cell carcinoma (HNSCC)
Fakultni Nemocnice Kralovske Vinohrady · 40 participants

📍 Czechia

2025-524720-22-00 on CTIS ↗

Phase I Cardiovascular Diseases Authorised 02/06/2026

Randomized, open-label, multiple dose, two-period, two-treatment, cross-over pharmacodynamic study in healthy male and female participants under fasting conditions.

Pharmacodynamic study under fasting condition.
Adamed Pharma S.A. · 42 participants

📍 Czechia

2026-526556-31-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 02/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1
Alkermes Inc. · 75 participants

📍 Italy · France · Netherlands · Spain · Belgium

2025-523911-13-00 on CTIS ↗

Phase III Immune System Diseases Authorised 02/06/2026

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

Systemic lupus erythematosus
AstraZeneca AB · 108 participants

📍 Poland · Germany · Italy · France · Spain

2025-523670-17-00 on CTIS ↗

Phase I Musculoskeletal Diseases Authorised 02/06/2026

An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.

treatment of myasthenia gravis
Vianex S.A. · 44 participants

📍 Czechia

2025-524219-35-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 02/06/2026

A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson’s disease – SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial

Parkinson's Disease
Helse Bergen HF · 45 participants

📍 Norway

2025-523570-17-00 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 01/06/2026

IMPD-Q-only application

prick test-induced itch
Incyte Corp. · 30 participants

📍 Austria

2025-524730-26-00 on CTIS ↗

Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS

Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG · 42 participants

📍 France · Austria · Poland · Netherlands · Spain · Denmark · Italy · Germany · Hungary

2025-522434-32-00 on CTIS ↗

Phase I Neoplasms Authorised 01/06/2026

GRAIN, Prospective Pilot Study

Esophageal dysplasia, Barrett's esophagus, Esophageal adenocarcinoma
Universitair Medisch Centrum Groningen · 52 participants

📍 Netherlands

2025-524470-41-00 on CTIS ↗

Phase III Virus Diseases Authorised 01/06/2026

Post-INFECT: Investigating Neuroinflammation and its eFEcts in post-COVID syndrome: an imaging sTudy

post-COVID syndrome
Amsterdam UMC Stichting · 65 participants

📍 Netherlands

2025-522349-23-00 on CTIS ↗

Phase III Immune System Diseases Authorised 01/06/2026

Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests

Allergy to Lepidoglyphus destructor
Inmunotek S.L. · 70 participants

📍 Spain

2025-523426-40-00 on CTIS ↗

Phase IV Skin and Connective Tissue Diseases Authorised 01/06/2026

IJAMP-Trial

prick test-induced itch
Johannes Kepler University Linz · 30 participants

📍 Austria

2025-523131-19-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 01/06/2026

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

Asthma
Novartis Pharma AG · 68 participants

📍 Poland · France · Slovakia · Spain · Hungary · Germany · Romania

2022-502365-26-00 on CTIS ↗

Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A

Hemophilia A
F. Hoffmann-La Roche AG · 124 participants

📍 Hungary · Spain · Ireland · Poland · Austria · Germany · Denmark · Belgium · Netherlands · Italy · France

2025-522435-33-00 on CTIS ↗

Phase II Neoplasms Authorised 01/06/2026

Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

Chronic Myeloid Leukemia
Grupo Espanol De Leucemia Mieloide Cronica (GELMC) · 30 participants

📍 Spain

2025-521126-15-00 on CTIS ↗

Phase III Neoplasms Authorised 01/06/2026

Use of DOTATOC labeled with V-Cu64 in PET-CT imaging of neuroendocrine tumors

Neoplasms
Voxel S.A. · 80 participants

📍 Poland

2025-524050-34-01 on CTIS ↗

Phase III Neoplasms Authorised 01/06/2026

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

Treatment-naїve mantle cell lymphoma (MCL)
Innocare Pharma Inc. · 102 participants

📍 Poland · France · Czechia · Spain · Romania

2025-524241-27-00 on CTIS ↗

Phase I/II Musculoskeletal Diseases Authorised 01/06/2026

A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease

Late-Onset Pompe Disease
Denali Therapeutics Inc. · 6 participants

📍 Germany · Netherlands

2025-524082-25-00 on CTIS ↗

Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026

MOOD - MethOxyflurane analgesia in vasoOcclusive crises of sickle cell Disease

Sickle cell disease
Assistance Publique Hopitaux De Paris · 198 participants

📍 France

2024-518043-38-00 on CTIS ↗

Phase II Immune System Diseases Authorised 29/05/2026

Sublingual Birch Immunotherapy for Pollen-associated Food Allergy

Pollen-associated Food Allergy, Birch pollen Allergy
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) · 96 participants

📍 Germany

2025-523653-34-00 on CTIS ↗

Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026

An open-label, single-arm, phase 1/2 first-in-human study to assess the safety and efficacy of autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene (SGX-001) in paediatric and adult patients with chronic granulomatous disease caused by p47phox deficiency

Chronic granulomatous disease (CGD) caused by p47phox deficiency (p47-CGD)
Somagenetix AG · 4 participants

📍 Germany · Spain

2025-524423-50-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 29/05/2026

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles · 86 participants

📍 Germany · France · Czechia · Netherlands · Spain

2024-516570-30-00 on CTIS ↗

Phase II Mental Disorders Authorised 29/05/2026

Leveraging the neural mechanisms of social reward for drug relapse prevention

substance use disorder
Fondazione Santa Lucia IRCCS · 70 participants

📍 Italy

2023-504518-31-01 on CTIS ↗

Phase II Nervous System Diseases Authorised 29/05/2026

Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS

Restless legs syndrome
Centre Hospitalier Universitaire De Montpellier · 60 participants

📍 France

2026-525613-31-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 29/05/2026

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study

heart failure
Centre Hospitalier Universitaire De Toulouse · 458 participants

📍 France

2025-524395-30-00 on CTIS ↗

Phase I/II Neoplasms Authorised 29/05/2026

C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.

Locally Advanced or Metastatic Urothelial Cancer
Pfizer Inc. · 36 participants

📍 Netherlands · Spain

2025-523523-21-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 29/05/2026

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

Schizophrenia and Autism Spectrum Disorder (ASD)
Bristol-Myers Squibb Services Unlimited Company · 40 participants

📍 Romania

2025-524062-16-00 on CTIS ↗

Phase III Neoplasms Authorised 29/05/2026

A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

Myelofibrosis
Novartis Pharma AG · 173 participants

📍 Belgium · Germany · Austria · Poland · Spain · Italy · Netherlands · Czechia · France

2025-523555-66-00 on CTIS ↗

Phase II Immune System Diseases Authorised 29/05/2026

J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Non-Segmental Vitiligo (NSV), Vitiligo
Eli Lilly & Co. · 14 participants

📍 Poland · Belgium

2025-524726-18-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 29/05/2026

Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.

Retractile Capsulitis
Centre Hospitalier Universitaire De Nantes · 38 participants

📍 France

2026-525317-31-00 on CTIS ↗

Phase III Therapeutics Authorised 29/05/2026

Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)

Deformity, Osteoarthritis
HUS-yhtymae · 450 participants

📍 Finland

2026-526142-27-01 on CTIS ↗

Phase III Immune System Diseases Authorised 29/05/2026

A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.

Grass pollen induced allergic rhinitis or rhinoconjunctivitis
Inmunotek S.L. · 450 participants

📍 Germany

2025-524580-21-00 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 29/05/2026

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Overweight Obesity
Eli Lilly & Co. · 115 participants

📍 Germany

2025-523873-41-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 29/05/2026

COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial

Chronic pancreatitis
Odense University Hospital · 80 participants

📍 Denmark

2025-522956-25-00 on CTIS ↗

Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic fibrosis
Vertex Pharmaceuticals Inc. · 80 participants

📍 Spain · Sweden · Germany · Italy · Belgium · Czechia · Ireland · Portugal · Netherlands · France · Denmark

2025-523400-72-00 on CTIS ↗

Phase III Neoplasms Authorised 29/05/2026

Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)

Hodgkin lymphoma
Polska Grupa Badawcza Chloniakow · 370 participants

📍 Poland

2026-525263-41-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 29/05/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Vertex Pharmaceuticals Inc. · 5 participants

📍 Poland

2025-523950-15-01 on CTIS ↗

Phase I Immune System Diseases Authorised 29/05/2026

A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis
Neurocrine Biosciences Inc. · 15 participants

📍 Poland · Romania

2025-525113-22-00 on CTIS ↗

Phase I/II Hemic and Lymphatic Diseases Authorised 29/05/2026

Prospective, multicentre, two-arms, I/II phase study to Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC)

Adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (PBL) with an indication to start treatment of relapsed disease according to IWCLL recommendations.
Uniwersytet Medyczny W Lublinie · 36 participants

📍 Poland

2024-513917-11-01 on CTIS ↗

Phase II Neoplasms Authorised 28/05/2026

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

Locally advanced high‑risk stage III rectal adenocarcinoma (non‑metastatic)
Institut Gustave Roussy · 24 participants

📍 France

2025-524378-40-00 on CTIS ↗

Phase II Neoplasms Authorised 28/05/2026

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)

Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences Inc. · 34 participants

📍 Bulgaria · France · Spain

2025-523539-20-00 on CTIS ↗

Phase III Bacterial Infections and Mycoses Authorised 28/05/2026

A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.

Helicobacter Pylori Infection
Verisfield Single Member S.A. · 420 participants

📍 Greece

2026-525291-26-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 28/05/2026

A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency

Alpha1-proteinase inhibitor deficiency, Alpha1 antitrypsin deficiency, Emphysema
CSL Behring LLC · 33 participants

📍 Denmark

2025-522964-33-00 on CTIS ↗

Phase IV Bacterial Infections and Mycoses Authorised 28/05/2026

A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial

Candidemia
University Of Cologne · 420 participants

📍 Germany

2026-525640-14-00 on CTIS ↗

Phase IV Anesthesia and Analgesia Authorised 28/05/2026

A randomized, Phase 4, double-blind, placebo-controlled, 6-arm crossover study to investigate the systemic effect of lidocaine and ropivacaine when used for Transversus Abdominis Plane (TAP) blocks on hyperalgesia and pain perception in healthy volunteers aged 18 to 64 years.

Acute pain
Oslo University Hospital HF · 20 participants

📍 Norway

2025-520910-67-01 on CTIS ↗

Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 28/05/2026

Optimising the protocol of labour induction using misoprostol – randomised open-label clinical trial (OPTIMISO)

Labour induction
Fakultni Nemocnice Brno · 200 participants

📍 Czechia

2026-525770-19-00 on CTIS ↗

Phase I/II Neoplasms Authorised 28/05/2026

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Merck Sharp & Dohme LLC · 73 participants

📍 Poland · Italy · France · Germany · Spain

2025-523005-15-00 on CTIS ↗

Phase II Virus Diseases Authorised 28/05/2026

Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)

Epstein-Barr virus infection
Helse Bergen HF · 45 participants

📍 Norway

2025-522781-77-01 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 28/05/2026

Bioavailability, Biopotency and Food effect study of SCD0503 compared to subcutaneous regular human insulin

Type 1 diabetes
Samchundang Pharm. Co. Ltd. · 16 participants

📍 Germany

2024-519502-12-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 27/05/2026

Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.

The medical condition studied in IMMUNO-BOS is Bronchiolitis obliterans syndrome (BOS) after allogeneic stem cell transplantation
Hospital Foch · 36 participants

📍 France

2024-516796-33-00 on CTIS ↗

Phase I/II Neoplasms Authorised 27/05/2026

A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC

Extensive stage small cell lung cancer
Novartis Pharma AG · 25 participants

📍 Spain · France

2025-523276-23-00 on CTIS ↗

Phase II Immune System Phenomena Authorised 27/05/2026

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials

moderate to severe rheumatoid arthritis (RA)
F. Hoffmann-La Roche AG · 46 participants

📍 Italy · Spain · Germany · France · Denmark · Poland · Belgium

2025-523579-47-00 on CTIS ↗

Phase I/II Neoplasms Authorised 27/05/2026

Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas

Sarcoma
Glaxosmithkline Research & Development Limited · 14 participants

📍 France

2025-523997-18-00 on CTIS ↗

Phase III Immune System Diseases Authorised 27/05/2026

A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

Moderately to Severely Active Crohn’s Disease
Janssen Cilag International · 302 participants

📍 Slovakia · Germany · Denmark · France · Spain · Italy · Netherlands · Belgium · Poland · Sweden · Austria · Czechia · Hungary

2025-521590-13-00 on CTIS ↗

Phase II Mental Disorders Authorised 27/05/2026

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Maplight Therapeutics Inc. · 85 participants

📍 Italy · Poland · Czechia · Portugal · Bulgaria · France · Slovakia · Romania · Hungary

2025-521757-16-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 26/05/2026

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

Duchenne muscular dystrophy
Solid Biosciences Inc. · 62 participants

📍 Spain · Netherlands · France · Italy · Belgium · Germany

2025-522949-22-00 on CTIS ↗

Phase I/II Neoplasms Authorised 26/05/2026

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

Neoplasm malignant
Merck Sharp & Dohme LLC · 22 participants

📍 France · Spain · Sweden · Germany · Italy · Belgium · Denmark · Hungary

2025-522339-32-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 26/05/2026

POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug

Chronic recurrent multifocal osteomyelitis (CRMO)
Assistance Publique Hopitaux De Paris · 30 participants

📍 France

2023-506420-93-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 26/05/2026

Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis

Osteoarthritis
Radboud universitair medisch centrum Stichting · 175 participants

📍 Netherlands

2025-524885-12-00 on CTIS ↗

Phase I Anesthesia and Analgesia Authorised 26/05/2026

A study comparing different dosage forms of midazolam and how they are taken up in the body.

Bioavailability Study under Fasting Conditions
MIDAS Pharma GmbH · 16 participants

📍 Czechia

2025-524999-37-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 26/05/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

Severe uncontrolled asthma
Generate Biomedicines Inc. · 80 participants

📍 Italy · Slovakia · Spain · Ireland · Belgium · France · Estonia

2025-524040-35-00 on CTIS ↗

Phase I Musculoskeletal Diseases Authorised 26/05/2026

First-in-human study to assess the safety and feasibility of intra-articular administration of allogeneic engineered gingival fibroblasts (aeGF) in participants with knee osteoarthritis.

Knee osteoarthritis
Scarcell Therapeutics · 10 participants

📍 Denmark

2026-525604-99-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 25/05/2026

Platelet function testing in outpatients after heart transplantation on aspirin therapy

Patients who have undergone heart transplantation.
Medical University Of Vienna · 100 participants

📍 Austria

2025-521699-71-01 on CTIS ↗

Phase III Immune System Diseases Authorised 25/05/2026

D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation

Allergy to Dermatophagoides pteronyssinus, Allergy to Dermatophagoides farinae
Inmunotek S.L. · 70 participants

📍 Spain

2025-522469-31-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 25/05/2026

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

relapsed/refractory multiple myeloma
C4 Therapeutics Inc. · 43 participants

📍 Italy · France · Spain · Poland

2025-524181-26-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 22/05/2026

Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices (OPIAC)

Intracranial aneurysms
Les Hopitaux Universitaires De Strasbourg · 244 participants

📍 France

2025-524884-18-01 on CTIS ↗

Phase II Neoplasms Authorised 22/05/2026

UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis

Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting
Unicancer · 51 participants

📍 France

2025-521982-29-00 on CTIS ↗

Phase I Not possible to specify Authorised 22/05/2026

A study in healthy people to compare two tablet formulations of pramipexole

Healthy volunteer trial
Boehringer Ingelheim International GmbH · 24 participants

📍 Germany

2026-525704-98-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 22/05/2026

Reassessment of statin-associated musscle symptoms in adults with familial hypercholesterolemia: A phase IV randomized double-blinded n-of-1 crossover trial including periods with atorvastatin, placebo and no study treatment

Familial hypercholesterolaemia
Oslo University Hospital HF · 70 participants

📍 Norway

2025-521589-83-00 on CTIS ↗

Phase I Immune System Diseases Authorised 22/05/2026

A study to test single and multiple doses of MER511 given to adults with Graves’ disease

Graves’ disease
Merida Biosciences Inc. · 28 participants

📍 Spain

2025-523823-23-00 on CTIS ↗

Phase I Not possible to specify Authorised 22/05/2026

Thorough QT/QTc study with GLPG3667, placebo, and active comparator in healthy subjects

Healthy volunteers
Galapagos · 25 participants

📍 Netherlands

2026-525788-42-00 on CTIS ↗

Phase I Behavior and Behavior Mechanisms Authorised 22/05/2026

A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

Neuropsychiatric indications and potentially other conditions
Bristol-Myers Squibb Services Unlimited Company · 12 participants

📍 Belgium

2025-524564-38-00 on CTIS ↗

Phase IV Neoplasms Authorised 22/05/2026

Comparing intraoperative indocyanine green fluorescence imaging with standard clinical assessment for flap perfusion in head and neck reconstruction: A randomised controlled Trial (VISION Trial)

Head and neck cancer
Region Skane · 244 participants

📍 Sweden

2025-524710-29-00 on CTIS ↗

Phase IV Bacterial Infections and Mycoses Authorised 22/05/2026

A randomized, placebo-controlled, blinded, parallel-group clinical trial to assess the efficacy of N-acetylcysteine in adults with acute infections or sepsis and evidence of liver dysfunction: the IMPACT-NAC trial

Acute infection, Sepsis
Region Hovedstaden · 360 participants

📍 Denmark

2026-525895-25-00 on CTIS ↗

Phase I Bacterial Infections and Mycoses Authorised 22/05/2026

A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 mg film-coated tablets (Antibiotice SA) vs. Normix® 200 mg, film- coated tablets (Alfasigma S.P.A) in healthy subjects under fed conditions

healthy subjects
Antibiotice S.A. · 64 participants

📍 Romania

2025-525078-12-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 22/05/2026

Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

Parkinson disease
Orion Corporation · 40 participants

📍 Czechia

2026-525448-14-00 on CTIS ↗

Phase II Eye Diseases Authorised 22/05/2026

Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression

Paediatric myopia
Laboratoires Thea · 20 participants

📍 Ireland

2025-521563-13-01 on CTIS ↗

Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 22/05/2026

Exogenous progesterone as ovulation trigger – a pilot study

Infertility
Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda. · 10 participants

📍 Portugal

2025-523850-15-00 on CTIS ↗

Phase I Immune System Diseases Authorised 22/05/2026

150 mg CIT-013 phase 1 trial

Immune mediated inflammatory diseases
Citryll B.V. · 10 participants

📍 Netherlands

2026-526153-34-00 on CTIS ↗

Phase III Neoplasms Authorised 22/05/2026

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

Unresectable Stage III non-small cell lung cancer without progression
Bristol-Myers Squibb Services Unlimited Company · 279 participants

📍 France · Ireland · Germany · Greece · Bulgaria · Spain · Netherlands · Italy · Sweden · Romania · Hungary · Belgium · Austria · Poland

2025-523576-23-00 on CTIS ↗

Phase II Male Urogenital Diseases Authorised 22/05/2026

A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).

Metastatic Castrate Sensitive Prostate Cancer - mCSPC
UroTrials GmbH, AIO-Studien gGmbH · 42 participants

📍 Germany

2025-523672-23-00 on CTIS ↗

Phase I/II Neoplasms Authorised 22/05/2026

A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours

Neoplasms benign malignant and unspecified (incl. cysts and polyps)
Orion Corporation · 85 participants

📍 Finland · Denmark · Spain · France

2025-524620-22-00 on CTIS ↗

Phase II Neoplasms Authorised 21/05/2026

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
Eikon Therapeutics Inc. · 115 participants

📍 Germany · Spain · Netherlands · Romania · Greece · Italy

2025-525013-23-00 on CTIS ↗

Phase I Respiratory Tract Diseases Authorised 21/05/2026

Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare

Chronic allergic rhinitis
Dianosic · 25 participants

📍 Netherlands

2026-525200-99-00 on CTIS ↗

Phase II Metabolism Authorised 21/05/2026

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

Adult patients with primary mitochondrial disease
Pharming Technologies B.V. · 96 participants

📍 Belgium · Germany · Czechia · Spain · Denmark · Italy · France

2025-524367-20-00 on CTIS ↗

Phase I Neoplasms Authorised 21/05/2026

First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

Neoplasms
Glaxosmithkline Research & Development Limited · 52 participants

📍 Spain · Denmark · Finland · France

2025-524165-25-00 on CTIS ↗

Phase IV Nutritional and Metabolic Diseases Authorised 21/05/2026

Effect of an adjunctive intervention on the tolerability of semaglutide in overweight adults without diabetes: a prospective, randomised, double-blind, single-centre, placebo-controlled clinical trial (SEMTOL)

Overweight and obesity
University Of Tartu · 100 participants

📍 Estonia

2025-524612-11-00 on CTIS ↗

Phase IV Neoplasms Authorised 21/05/2026

Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma

Renal cell carcinoma
Centro Di Riferimento Oncologico Di Aviano · 216 participants

📍 Italy

2026-525267-40-00 on CTIS ↗

Phase II Eye Diseases Authorised 20/05/2026

An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up

Thyroid Eye Disease
Amgen Inc. · 8 participants

📍 Spain · Poland · France · Italy

2025-523280-38-00 on CTIS ↗

Phase III Skin and Connective Tissue Diseases Authorised 20/05/2026

An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib

Chronic Spontaneous Urticaria
Novartis Pharma AG · 154 participants

📍 Germany · Spain · France · Poland · Bulgaria · Czechia

2025-524078-40-00 on CTIS ↗

Phase I/II Genetic Phenomena Authorised 20/05/2026

An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)

X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)
Fondazione Telethon Ets, San Raffaele Hospital · 4 participants

📍 Italy

2025-524635-39-00 on CTIS ↗

Phase I Immune System Diseases Authorised 20/05/2026

SAR447971 first-in-human study

Hidradenitis
Sanofi-Aventis Recherche & Developpement · 134 participants

📍 Netherlands

2026-525333-22-00 on CTIS ↗

Phase III Immune System Diseases Authorised 20/05/2026

A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa

Hidradenitis Suppurativa (HS)
Novartis Pharma AG · 307 participants

📍 Portugal · Greece · Germany · Hungary · France · Spain · Bulgaria · Slovakia · Poland · Czechia · Belgium · Italy

2025-523259-72-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 20/05/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

Duchenne muscular dystrophy
Avidity Biosciences Inc. · 42 participants

📍 Italy · Germany · France · Spain · Belgium · Poland · Netherlands

2025-523087-20-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 20/05/2026

Erdosteine effect on oxidative stress, inflammatory response and immune modulation in patients with COPD. A single center, open label, double arm, controlled, 4-week, explorative, ex vivo study.

COPD
ASST Fatebenefratelli Sacco · 30 participants

📍 Italy

2025-524821-42-00 on CTIS ↗

Phase II Immune System Diseases Authorised 19/05/2026

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Rheumatoid arthritis
Elevara Medicines Limited · 95 participants

📍 Czechia · Bulgaria · Hungary · Netherlands · Poland · Spain

2025-524005-32-00 on CTIS ↗

Phase I Digestive System Diseases Authorised 19/05/2026

An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

Active Ulcerative Colitis (UC)
F. Hoffmann-La Roche AG · 19 participants

📍 Germany · Poland · Belgium

2025-524060-38-00 on CTIS ↗

Phase II Immune System Diseases Authorised 19/05/2026

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis
Janssen Cilag International · 14 participants

📍 Germany · Poland

2025-523464-20-00 on CTIS ↗

Phase III Neoplasms Authorised 19/05/2026

Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial

Metastatic hormone-sensitive prostate cancer
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard · 292 participants

📍 Spain · Germany · France · Portugal · Italy

2025-524408-30-01 on CTIS ↗

Phase III Hemic and Lymphatic Diseases Authorised 19/05/2026

A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)

Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding
VarmX B.V. · 443 participants

📍 Belgium · Germany · Italy · France · Czechia · Bulgaria · Hungary · Spain · Netherlands · Poland · Austria · Estonia · Romania · Portugal · Lithuania

2025-521632-12-00 on CTIS ↗

Phase II Nutritional and Metabolic Diseases Authorised 19/05/2026

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

Proteinuric kidney diseases
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 66 participants

📍 Portugal · Greece · Italy · Poland · Estonia · Slovakia · Sweden · Denmark · Belgium · Norway · Romania · France · Spain · Germany · Netherlands · Croatia

2025-523425-17-00 on CTIS ↗

Phase II Neoplasms Authorised 19/05/2026

Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations

locally advanced or metastatic NSCLC
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 19 participants

📍 Germany · France · Spain

2025-523567-38-00 on CTIS ↗

Phase II Neoplasms Authorised 19/05/2026

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma

Neuroblastoma or ganglioneuroblastoma (nodular or intermixed)
Fundacio Sant Joan De Deu · 22 participants

📍 Spain

2025-524140-35-00 on CTIS ↗

Phase II Neoplasms Authorised 19/05/2026

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

Patients With Muscle-Invasive Bladder Cancer
AstraZeneca AB · 60 participants

📍 Italy · Spain · France · Netherlands

2024-519246-75-01 on CTIS ↗

Phase III Virus Diseases Authorised 19/05/2026

A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming. "BAZOOKA_221"

Rabies infection/prophylaxis
Institute Of Tropical Medicine · 561 participants

📍 Belgium

2025-524765-24-00 on CTIS ↗

Phase II Neoplasms Authorised 19/05/2026

A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone

Acute myeloid leukemia
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe · 40 participants

📍 Italy · Spain

2025-524308-31-00 on CTIS ↗

Phase III Neoplasms Authorised 19/05/2026

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corp. · 292 participants

📍 Poland · France · Denmark · Norway · Spain · Germany · Belgium · Netherlands · Austria · Italy

2025-523735-19-00 on CTIS ↗

Phase III Bacterial Infections and Mycoses Authorised 19/05/2026

Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).

Recurrent Non-Complicated Urinary Tract Infections (rUTIs).
Inmunotek S.L. · 252 participants

📍 Portugal

2025-524377-16-00 on CTIS ↗

Phase III Bacterial Infections and Mycoses Authorised 18/05/2026

Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).

Neisseria gonorrhoeae Infections
Assistance Publique Hopitaux De Paris · 360 participants

📍 France

2025-524475-23-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 18/05/2026

A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease

Parkinson's Disease
Mission Therapeutics Limited · 18 participants

📍 Germany · Netherlands · France

2024-517310-15-00 on CTIS ↗

Phase IV Reproductive and Urinary Physiological Phenomena Authorised 18/05/2026

A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative

Male Infertility
Martin-Luther-Universitaet Halle-Wittenberg · 138 participants

📍 Italy · Spain · Germany

2025-525005-20-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 18/05/2026

EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections

Pleural infections
Centre Hospitalier Universitaire Amiens Picardie · 244 participants

📍 France

2025-524697-42-00 on CTIS ↗

Phase II Nutritional and Metabolic Diseases Authorised 18/05/2026

INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an “add-on” Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial

Incremental Haemodialysis
Centre Hospitalier Le Mans · 70 participants

📍 France

2025-524093-41-00 on CTIS ↗

Phase I Immune System Diseases Authorised 18/05/2026

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

human immunodeficiency virus (HIV)
Viiv Healthcare UK Limited · 9 participants

📍 Netherlands

2026-525590-40-00 on CTIS ↗

Phase II Nutritional and Metabolic Diseases Authorised 18/05/2026

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.

Exocrine Pancreatic Insufficiency
Aimmune Nestle Health Science US R&D LLC · 29 participants

📍 Poland · Hungary · Spain · Bulgaria · Italy

2025-521816-20-00 on CTIS ↗

Phase III Immune System Diseases Authorised 18/05/2026

Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Blomia tropicalis

Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma
Inmunotek S.L. · 120 participants

📍 Spain

2025-522773-12-00 on CTIS ↗

Phase II Bacterial Infections and Mycoses Authorised 18/05/2026

Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV

Asymptomatic anal LGV infection
Centre Hospitalier Universitaire De Bordeaux · 120 participants

📍 France

2025-524978-42-00 on CTIS ↗

Phase I/II Hemic and Lymphatic Diseases Authorised 18/05/2026

mRNA Therapy to restore lymphatic flow in secondary lymphedema

Lymphedema
Centre Hospitalier Universitaire De Toulouse · 9 participants

📍 France

2024-520149-22-00 on CTIS ↗

Phase IV Neoplasms Authorised 18/05/2026

Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”

Gastroenteropancreatic neuroendocrine tumors
Centre De Lutte Contre Le Cancer Eugene Marquis · 40 participants

📍 France

2025-524942-87-00 on CTIS ↗

Phase I/II Neoplasms Authorised 18/05/2026

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer

Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 21 participants

📍 Italy · Spain · Romania

2025-524090-16-00 on CTIS ↗

Phase II Neoplasms Authorised 18/05/2026

TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)

Advanced pancreatic cancer
Region Hovedstaden · 1200 participants

📍 Denmark

2025-522431-34-00 on CTIS ↗

Phase II Neoplasms Authorised 18/05/2026

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene
AbbVie Deutschland GmbH & Co. KG · 29 participants

📍 Spain · France · Denmark

2024-518871-74-00 on CTIS ↗

Phase II Immune System Diseases Authorised 18/05/2026

THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation

Sepsis, Hyperinflammation
Prinses Maxima Centrum voor Kinderoncologie B.V. · 76 participants

📍 Netherlands

2025-524541-27-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 18/05/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC · 398 participants

📍 Italy · Finland · Bulgaria · Greece · Belgium · Estonia · Portugal · Spain · Germany · France · Czechia · Slovakia · Romania · Croatia · Poland · Austria · Netherlands · Denmark · Sweden · Hungary

2025-524316-11-00 on CTIS ↗

Phase II Neoplasms Authorised 18/05/2026

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation
Novartis Pharma AG · 15 participants

📍 Spain · France · Germany · Poland · Italy · Netherlands · Greece

2025-522138-29-00 on CTIS ↗

Phase IV Cardiovascular Diseases Authorised 18/05/2026

The effect of beta-blockers on how you feel and recover after a heart attack when your heart is still pumping well

Myocardial infarction with preserved ejection fraction
UZ Leuven · 160 participants

📍 Belgium

2026-525475-96-00 on CTIS ↗

Phase IV Respiratory Tract Diseases Authorised 18/05/2026

A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.

Asthma
Chiesi Farmaceutici S.p.A. · 606 participants

📍 Germany · Romania · Italy · Bulgaria · Poland · Slovakia · Spain · France

2025-524289-56-00 on CTIS ↗

Phase III Neoplasms Authorised 18/05/2026

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 157 participants

📍 Spain · Norway · Germany · Greece · France · Italy · Netherlands

2025-522007-18-00 on CTIS ↗

Phase I Neoplasms Authorised 18/05/2026

A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors

advanced refractory solid tumors
Samsung Bioepis Co. Ltd. · 40 participants

📍 Spain

2025-524192-24-00 on CTIS ↗

Phase II Surgical Procedures, Operative Authorised 17/05/2026

SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.

Kidney Transplant Recipient
Medical University Of Vienna · 120 participants

📍 Austria

2025-525091-29-00 on CTIS ↗

Phase III Neoplasms Authorised 15/05/2026

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%

Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 265 participants

📍 Portugal · Norway · Sweden · Bulgaria · France · Belgium · Austria · Germany · Finland · Poland · Romania · Netherlands · Spain · Italy · Hungary · Czechia

2025-523586-18-00 on CTIS ↗

Phase I/II Immune System Diseases Authorised 15/05/2026

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc. · 28 participants

📍 Poland

2025-525127-27-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 15/05/2026

A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

Recurrent glioblastoma
Oncopeptides AB · 10 participants

📍 Norway

2026-525543-32-00 on CTIS ↗

Phase I/II Neoplasms Authorised 15/05/2026

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

Advanced Solid Tumors
Eikon Therapeutics Inc. · 63 participants

📍 France · Spain · Norway · Italy · Germany · Austria · Poland · Finland · Portugal

2026-525248-13-00 on CTIS ↗

Phase I Nutritional and Metabolic Diseases Authorised 15/05/2026

Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

Healthy Overweight or Obese
F. Hoffmann-La Roche AG · 60 participants

📍 Netherlands

2025-524052-58-00 on CTIS ↗

Phase III Neoplasms Authorised 15/05/2026

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)

triple-negative early breast cancer
WSG Westdeutsche Studiengruppe GmbH · 690 participants

📍 Germany

2024-516734-35-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 15/05/2026

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

Participants with overweight or obesity, and type 2 diabetes
Novo Nordisk A/S · 440 participants

📍 Germany · Croatia · Portugal · Hungary · Bulgaria · Romania · Poland

2024-520446-31-00 on CTIS ↗

Phase II Neoplasms Authorised 14/05/2026

A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Relapsed or Refractory Multiple Myeloma (RRMM)
Janssen Cilag International · 54 participants

📍 Poland · Italy

2025-521976-80-00 on CTIS ↗

Phase III Immune System Diseases Authorised 14/05/2026

Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Lepidoglyphus destructor.

Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma
Inmunotek S.L. · 120 participants

📍 Spain

2025-522771-28-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 14/05/2026

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

Relapsed/refractory primary central nervous system lymphoma
Deciphera Pharmaceuticals Inc. · 74 participants

📍 Czechia · Germany · Italy · Belgium · Spain · Poland · Austria · France

2025-523389-26-00 on CTIS ↗

Phase III Neoplasms Authorised 13/05/2026

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia
Quetzal Therapeutics LLC · 89 participants

📍 Germany · Poland · Spain · Romania · Italy · France

2025-524810-28-00 on CTIS ↗